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1. SUMMARY
1.1 Introduction
The breast cancer screening programmes in the United Kingdom
currently invite women aged 50–70 years for screening mammo-
graphy every 3 years. Since the time the screening programmes
were established, there has been debate, at times sharply polarised,
over the magnitude of their benefit and harm, and the balance
between them. The expected major benefit is reduction in
mortality from breast cancer. The major harm is overdiagnosis
and its consequences; overdiagnosis refers to the detection
of cancers on screening, which would not have become clinically
apparent in the woman’s lifetime in the absence of screening.
Professor Sir Mike Richards, National Cancer Director,
England, and Dr Harpal Kumar, Chief Executive Officer of
Cancer Research UK, asked Professor Sir Michael Marmot to
convene and chair an independent panel to review the evidence
on benefits and harms of breast screening in the context of
the UK breast screening programmes. The panel, authors of this
report, reviewed the extensive literature and heard testimony
from experts in the field who were the main contributors to the
debate.
The nature of information communicated to the public, which
too has sparked debate, was not part of the terms of reference of
the panel, which are listed in Appendix 1.
1.2 Relative mortality benefit
The purpose of screening is to advance the time of diagnosis so
that prognosis can be improved by earlier intervention. A
consequence of earlier diagnosis is that it increases the apparent
incidence of breast cancer in a screened population and extends the
average time from diagnosis to death, even if screening were to
confer no benefit. The appropriate measure of benefit, therefore, is
reduction in mortality from breast cancer in women offered
screening compared with women not offered screening.
In the panel’s judgement, the best evidence for the relative benefit
of screening on mortality reduction comes from 11 randomised
controlled trials (RCTs) of breast screening. Meta-analysis of these
trials with 13 years of follow-up estimated a 20% reduction in breast
cancer mortality in women invited for screening. The relative
reduction in mortality will be higher for women actually attending
screening, but by how much is difficult to say because women who do
not attend are likely to have a different background risk. Three types
of uncertainties surround this estimate of 20% reduction in breast
cancer mortality. The first is statistical: the 95% confidence interval
(CI) around the relative risk (RR) reduction of 20% was 11–27%. The
second is bias: there are a number of potential sources of distortion
in the trials that have been widely discussed in the literature ranging
from suboptimal randomisation to problems in adjudicating cause of
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death. The third is the relevance of these old trials to the current
screening programmes. The panel acknowledged these uncertainties,
but concluded that a 20% reduction is still the most reasonable
estimate of the effect of the current UK screening programmes on
breast cancer mortality. Most other reviews of the RCTs have yielded
similar estimates of relative benefit.
The RCTs were all conducted at least 20–30 years ago. More
contemporary estimates of the benefit of breast cancer screening come
from observational studies. The panel reviewed three types of
observational studies. The first were ecological studies comparing
areas, or time periods, when screening programmes were and were
not in place. These have generated diverse findings, partly because of
the major advances in treatment of breast cancer, which have a
demonstrably larger influence on mortality trends than does screen-
ing, and partly because of the difficulty of excluding imbalances in
other factors that could affect breast cancer mortality. The panel did
not consider these studies helpful in estimating the effect of screening
on mortality. The other two types of studies, case–control studies and
incidence-based mortality studies, showed breast screening to confer a
greater benefit than did the trials. Although these studies, in general,
attempted to control for non-comparability of screened and
unscreened women, the panel was concerned that residual bias could
inflate the estimate of benefit. However, the panel notes that these
studies’ findings are in the same direction as the trials.
1.3 Absolute mortality benefit
Estimates of absolute benefit of screening have varied from one breast
cancer death avoided for 2000 women invited to screening to 1 avoided
for about 100 women screened, about a 20-fold difference. Major
determinants of that large variation are the age of women screened, and
the durations of screening and follow-up. The age of the women
invited is important, as mortality from breast cancer increases
markedly with age. The panel therefore applied the relative mortality
reduction of 20% to achieve the observed cumulative absolute risk of
breast cancer mortality over the ages 55–79 years for women in the
United Kingdom, assuming that women who began screening at 50
years would gain no benefit in the first 5 years, but that the mortality
reduction would continue for 10 years after screening ended. This
yielded the estimate that for every 235 women invited to screening, one
breast cancer death would be prevented; correspondingly 180 women
would need to be screened to prevent one breast cancer death.
Uncertainties in the figure of a 20% RR reduction would carry through
to these estimates of absolute mortality benefit. Nonetheless, the panel’s
estimate of benefit is in the range of one breast cancer death prevented
for B250 women invited, rather than the range of 1 in 2000.
1.4 Overdiagnosis
The major harm of screening considered by the panel was that of
overdiagnosis. Given the definition of an overdiagnosed cancer, either
invasive or non-invasive, as one diagnosed by screening, which would
not otherwise have come to attention in the woman’s lifetime, there is
need for a long follow-up to assess the frequency of overdiagnosis. In
the view of the panel, some cancers detected by screening will be
overdiagnosed, but the uncertainty surrounding the extent of over-
diagnosis is greater than that for the estimate of mortality benefit
because there are few sources of reliable data. The issue for the UK
screening programmes is the magnitude of overdiagnosis in women
who have been in a screening programme from age 50 to 70, then
followed for the rest of their lives. There are no data to answer this
question directly. Any estimate will therefore be, at best, provisional.
Although the definition of an overdiagnosed case, and thus the
numerator in a ratio, is clear, the choice of denominator has been the
source of further variability in published estimates. Different studies
have used: only the cancers found by screening; cancers found during
the whole screening period, both screen-detected and interval; cancers
diagnosed during the screening period and for the remainder of the
women’s lifetime. The panel focused on two estimates: the first from a
population perspective using as the denominator the number of breast
cancers, both invasive and ductal carcinoma in situ (DCIS), diagnosed
throughout the rest of a woman’s lifetime after the age that screening
begins, and the second from the perspective of a woman invited to
screening using the total number of breast cancers diagnosed during
the screening period as the denominator.
The panel thought that the best evidence came from three RCTs
that did not systematically screen the control group at the end of
the screening period and followed these women for several more
years. The frequency of overdiagnosis was of the order of 11% from
a population perspective, and about 19% from the perspective of a
woman invited to screening. Trials that included systematic
screening of the control group at the end of the active part of
the trial were not considered to provide informative estimates of
the frequency of overdiagnosis.
Information from observational studies was also considered. One
method that has been used is investigation of time trends in
incidence rates of breast cancer for different age groups over the
period that population screening was introduced. The published
results of these studies varied greatly and have been interpreted as
providing either reassurance or cause for alarm. So great was the
variation in results that the panel conducted an exercise by varying
the assumptions and statistical methods underlying these studies,
using the same data sets; estimates of overdiagnosis rates were found
to vary across the range of 0–36% of invasive breast cancers
diagnosed during the screening period. The panel had no reason to
favour one set of estimates over another, and concluded that this
method could give no reliable estimate of the extent of overdiagnosis.
Were it possible to distinguish at screening those cancers that
would not otherwise have come to attention from those that,
untreated, would lead to death, the overdiagnosis problem could be
much reduced, at least in terms of unnecessary worry and
treatment. Currently this is not possible, so neither the woman
nor her doctor can know whether a screen-detected cancer is an
‘overdiagnosed’ case or not. In particular, DCIS, most often
diagnosed at screening, does not inevitably equate to overdiagnosis
– screen-detected DCIS, after wide local excision (WLE) only, is
associated with subsequent development of invasive breast cancer
in 10% of women within 10 years.
The consequences of overdiagnosis matter, women are turned
into patients unnecessarily, surgery and other forms of cancer
treatment are undertaken, and quality of life and psychological well
being are adversely affected.
1.5 The balance of benefit and harm
The panel estimates that an invitation to breast screening delivers
about a 20% reduction in breast cancer mortality. For the UK
screening programmes, this currently corresponds to about 1300
deaths from breast cancer being prevented each year, or equivalently
about 22 000 years of life being saved. However, this benefit must be
balanced against the harms of screening, especially the risk of
overdiagnosis. In the panel’s view, overdiagnosed cancers certainly
occur, but the frequency in a screening programme of 20 years
duration is unknown. Estimates from trials of shorter duration
suggest overdiagnosis of about 11% as a proportion of breast cancer
incidence during the screening period and for the remainder of the
woman’s lifetime, or equivalently about 19% as a proportion of
cancers diagnosed during the screening period. Any excess mortality
stemming from the investigation and treatment of breast cancer is
considered by the panel to be small and considerably outweighed by
the benefits of treatment. Some other harms, including increased
anxiety and discomfort caused by screening, are also acknowledged.
Notionally, for 10 000 women invited to screening, from age 50
for 20 years, it is estimated that 681 cancers (invasive and DCIS)
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will be diagnosed, of which 129 will represent overdiagnosis (using
the 19% estimate of overdiagnosis) and 43 deaths from breast
cancer will be prevented.
Given that the treatment for breast cancer has improved, is
screening no longer relevant? The panel’s view is that the benefits
of screening and those of better treatments are reasonably
considered independent. Uncertainty about possible interaction
between the benefits of screening and of contemporary treatments
is not a reason for stopping breast screening.
The panel was not asked to comment on costs, both of interventions
and the consequences of overdiagnosis. With accurate figures an
estimate of cost-benefit could be made and compared with other
interventions, but would be a significant piece of work in its own right.
An individual woman cannot know whether she is one of the
numbers who will benefit or be harmed from screening. If she chooses
to be screened, it should be in the knowledge that she is accepting the
chance of benefit, having her life extended, knowing that there is also
a risk of overdiagnosis and unnecessary treatment. Similarly, a woman
who declines the invitation to screening needs to recognise that she
runs a slightly higher risk of dying from breast cancer.
1.6 Conclusions and recommendations
Breast screening extends lives. The panel’s review of the evidence
on benefit – the older RCTs, and those more recent observational
studies – points to a 20% reduction in mortality in women invited
to screening. A great deal of uncertainty surrounds this estimate,
but it represents the panel’s overview of the evidence. This
corresponds to one breast cancer death averted for every 235
women invited to screening for 20 years, and one death averted for
every 180 women who attend screening.
The panel’s best estimate is that the breast screening
programmes in the United Kingdom, inviting women aged
50–70 every 3 years, prevent about 1300 breast cancer deaths a
year, a most welcome benefit to women and to the public health.
However, there is a cost to women’s well being. In addition to
extending some lives by early detection and treatment, mammo-
graphic screening detects cancers, proven to be cancers by
pathological testing, that would not have come to clinical attention
in the woman’s life, were it not for screening - called overdiagnosis.
The consequence of overdiagnosis is that women have their cancer
treated by surgery, radiotherapy and medication, but neither the
woman nor her doctor can know whether this particular cancer
would be one that could possibly lead to death, or one that would
have remained undetected for the rest of the woman’s life.
The panel sought to estimate the level of overdiagnosis in
women screened for 20 years and followed to the end of their lives.
Estimates of overdiagnosis abound, from near to zero to 50%, but
there is a paucity of reliable data to answer this question. There has
not even been agreement on how to measure overdiagnosis. On the
basis of follow-up of three RCTs, the panel estimated that in
women invited to screening, about 11% of the cancers diagnosed in
their lifetime constitute overdiagnosis, and about 19% of the
cancers diagnosed during the period that women are actually in the
screening programme; but the panel emphasises these figures are
the best estimates from a paucity of reliable data.
Putting together benefit and overdiagnosis from the above figures,
the panel estimates that for 10 000 UK women invited to screening
from age 50 for 20 years, about 681 cancers will be found of which
129 will represent overdiagnosis, and 43 deaths from breast cancer
will be prevented. In round terms, therefore, for each breast cancer
death prevented, about three overdiagnosed cases will be identified
and treated. Of theB307 000 women aged 50–52 who are invited to
screening each year, just 41% would have an overdiagnosed cancer
during the next 20 years. Given the uncertainties around the
estimates, the figures quoted give a spurious impression of accuracy.
The panel concludes that the UK breast screening programmes
confer significant benefit and should continue. The greater the pro-
portion of women who accept the invitation to be screened, the greater
is the benefit to the public health in terms of reduction in mortality
from breast cancer. However for each woman the choice is clear: on the
plus side screening confers a likely reduction in mortality from breast
cancer because of early detection and treatment. On the negative side,
is the knowledge that she has perhaps a 1% chance of having a cancer
diagnosed, and treated with surgery and other modalities, which would
never have caused problems had she not been screened.
Evidence from a focus group conducted by Cancer Research UK
and attended by two panel members, and in line with previous similar
studies, was that this was an offer many women will feel is worth
accepting: the treatment of overdiagnosed cancer may cause suffering
and anxiety, but that suffering is worth the gain from the potential
reduction in breast cancer mortality. Clear communication of these
harms and benefits to women is of utmost importance and goes to the
heart of how a modern health system should function. There is a body
of knowledge on how women want information presented, and this
should inform the design of information to the public.
2. INTRODUCTION
2.1 The UK NHS breast screening programmes
The NHS breast cancer screening programme in England began
inviting women to be screened in 1988. This followed the
recommendations made by Professor Sir Patrick Forrest in his
report on breast screening in 1986 (Forrest, 1986). The breast
screening programmes in the United Kingdom currently invite
women aged 50–70 years for a screening mammography every 3
years. The mammography is designed to detect changes in the
breast tissue that may indicate the presence of cancer. The
screening programme in England is currently conducting a
randomised trial to ascertain whether there would be benefit in
extending the age at which women are invited to 47–73 years.
2.2 Principles of screening
Screening is concerned with the detection of disease at an
early stage, with the expectation that treatment will be more
effective if begun earlier in the disease process. Screening is
therefore based on the principle of there being an effective
treatment. It is well recognised that an apparent benefit
of increased survival time could be illusory because of simply
bringing forward the time of diagnosis without changing the
course of the disease. Therefore, the appropriate way to assess
benefit is to look at breast cancer mortality of screened and
unscreened cohorts rather than just survival time from diagnosis
(see section 3).
As the principle of screening is to diagnose cases earlier,
at any particular time point during the period of suc-
cessive screenings, there will be more cases of breast cancer in a
group of screened women compared with a similar group of
unscreened women. However, it is possible that some of these
additional cases may be cancers that would not otherwise
have been diagnosed or caused the woman any problem during
her lifetime. These cancers are referred to as overdiagnosis
(see section 4).
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2.3 The debate over benefits and harms of breast screening
Since the screening programmes were established, there has been
debate over the potential benefits and harms. Recently, the debate
has focussed on the reduction in mortality attributable to
screening, the numbers of women overdiagnosed, and the way
that the risks and benefits are communicated to women invited for
screening. The arguments have become quite polarised between
those who believe that the benefit of decreased breast cancer
mortality outweighs the harms and those who believe the harms
outweigh the benefit. These differing views of the evidence have
arisen, in part, from disagreements over the validity and
applicability of the available RCTs of breast screening, and from
questions about the usefulness and interpretation of observational
data on breast cancer incidence and mortality.
The debate over the benefits and harms of breast screening is not
unique to the UK and the NHS breast screening programmes. In
2002, the International Agency for Research on Cancer at the World
Health Organisation reviewed the evidence on breast screening, and
put forward recommendations on further research and on imple-
menting screening programmes (IARC, 2002). The US Preventive
Services Task Force in 2009 re-examined the efficacy of different
screening modalities. They recommended that women under the age
of 50 not be routinely screened, and that women aged 50–74 have
biennial rather than annual screens (Woolf, 2010). The Canadian
Taskforce on Preventative Health Care updated their guidelines on
breast screening in 2011, and concluded that the reduction in
mortality associated with screening mammography is small for
women aged 40–74 years at average risk of breast cancer. They also
found a greater reduction in mortality for women aged X50
compared with those o50, and that harms of overdiagnosis and
unnecessary biopsy may be greater for younger women than for older
women. They recommended that women aged 50–74 be routinely
screened but state that appreciable uncertainty exists around the
evidence for this (Canadian Task Force on Preventive Health Care,
2011). Published reports from the Nordic Cochrane Centre concluded
that, despite their substantial methodological limitations, the trials of
screening showed that screening saved lives, but at the cost of
considerable harm from overdiagnosis (Gøtzsche and Nielsen, 2011).
2.4 Breast cancer in the UK
Incidence and mortality
In the United Kingdom, breast cancer remains the most commonly
diagnosed cancer in women (48 417 cases in 2009) and is the
second most common cause of death from cancer in women
(11 556 deaths in 2010). UK breast cancer incidence rates have been
rising in all age groups since the late 1970s (Figure 1A). The causes
of these increasing rates are thought to include: increased use of
hormone replacement therapy; later age at child birth; lower parity;
and increasing obesity and alcohol intake in women. Also, there is
believed to be better ascertainment, especially in older women. In
common with most countries, the introduction of the screening
programme for women aged 50–64 in 1988 and those aged 65–70 in
2001 led to additional increases in incidence (Figure 1A).
By contrast with incidence rates, since the early 1990s, the
mortality rates for breast cancer have been decreasing – shown both
as annual mortality rates and 35-year cumulative risk of dying from
breast cancer (Figure 1B). It is believed that the causes of these
decreases may include: improvement in treatment, in particular
adjuvant therapies; specialisation and better organisation of cancer
care; screening; and increased breast awareness (Appendix 2).
Contribution of screening to decreased breast cancer mortality
It is widely agreed that screening alone cannot be the major factor
responsible for the decrease in breast cancer mortality over the last
20 years. Improvements in treatment and service delivery are likely
to have made the largest contribution to decreased mortality (Berry
et al, 2005). Indeed, without effective treatment, screening for breast
cancer is redundant. However, it is important to establish what
contribution, if any, screening makes, given that it requires the use
of substantial resources within the health system, and nearly two
million women each year in England alone accept the invitation and
agree to be screened (The NHS Information Centre, 2012).
2.5 Independent review of breast screening
It is within this context that Professor Sir Mike Richards, National
Cancer Director, England and Dr Harpal Kumar, Chief Executive
Officer of Cancer Research UK, asked Professor Sir Michael
Marmot to chair an independent panel to review breast screening.
The panel’s terms of reference are shown in Appendix 1. This panel
has reviewed the extensive literature and heard testimony from
many of the experts in the field. This report details its findings and
recommendations for the breast screening programme in England.
2.6 Independent review panel membership
The independent panel consisted of nationally and internationally
recognised experts in epidemiology and/or medical statistics, as well
as in current breast cancer diagnosis and treatment practices. A
patient advocate was an integral member of the panel. No panel
member had previously published on breast screening, thus helping
to ensure an objective and independent assessment of the evidence.
The panel was chaired by Professor Sir Michael G Marmot,
Director of the Institute of Health Equity, University College
London; Chair, WHO Commission on Social Determinants of
Health; Chair, Marmot Review – Strategic Review of Health
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Figure 1. (A) European age-standardised incidence rates per 1 00000
population, females, by age, Great Britain. (B) Breast cancer mortality
at ages 35–69, UK, 1950–2009 (World Health Organization, 2012).
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Inequalities in England after 2010; Chair, European Review on the
Social Determinants of Health and the Health Divide; MRC
Research Professor of Epidemiology and Public Health, University
College London with long-standing research on social determi-
nants of health and health inequalities.
The other panellists were:
Professor Douglas G Altman, Director of the Centre for
Statistics in Medicine and Cancer Research UK Medical Statistics
Group, University of Oxford. Doug’s varied research interests
include the use and abuse of statistics in medical research, studies
of prognosis, regression modelling, systematic reviews, randomised
trials, and studies of medical measurement. He is actively involved
in efforts to improve the quality of scientific publications by
promoting transparent and accurate reporting of health research.
Professor David A Cameron, Clinical Director of the Edinburgh
Cancer Research Centre, Director of Cancer Services at NHS Lothian,
and Professor of Oncology at Edinburgh University. Previously,
David was the Director of the NIHR National Cancer Research
Network and Professor of Oncology at Leeds University. His research
interests are in translational and clinical trials in breast cancer, and he
is the principal investigator of several clinical trials looking at
treatment of early breast cancer. Before qualifying as a medical
doctor, he completed an undergraduate degree in Mathematics.
Professor John A Dewar, Consultant and honorary Professor of
Clinical Oncology. Until recently, John was Head of Oncology at
Ninewells Hospital, Dundee. John has a long-standing interest in
the management of patients with breast cancer and has been
closely involved in clinical trials of both radiotherapy and systemic
therapy for breast cancer.
Professor Simon G Thompson, Director of Research in
Biostatistics at the University of Cambridge. Simon’s research
interests are in meta-analysis and evidence synthesis, clinical trial
methodology, health economic evaluation, and cardiovascular
epidemiology. He has collaborated on a number of major clinical
trials, recently including all the major UK national trials of
screening and treatment for abdominal aortic aneurysms.
Maggie Wilcox, patient advocate. Maggie was a health visitor for
many years before working as Clinical Nurse Specialist in palliative
care before her breast cancer diagnosis in 1997. After early
retirement following her treatment, she became involved in patient
advocacy in cancer services and research. She now provides a patient
voice at national and local level as a member of various
organisations, including the National Cancer Research Institute
Breast Clinical Study Group and the Surrey, West Sussex and
Hampshire Network Breast Site Specific Group.
2.7 Independent review process and role of secretariat
As set out in the review’s terms of reference, the secretariat
provided initial key literature on breast cancer screening, including
publications recommended from both sides of the debate. The
panel then called on a range of experts (see Appendix 1 for full list)
to give evidence.
Cancer Research UK and the Department of Health provided
the secretariat function for the review comprising:
 Dr Dulcie McBride, Consultant in Public Health Medicine,
Department of Health
 Sara Hiom, Director of Information, Cancer Research UK
 Nick Ormiston-Smith, Data Analysis and Research Manager,
Cancer Research UK
 Dr Martine Bomb, Programme Manager, Cancer Research UK
 Samantha Harrison, Programme Officer, Cancer Research UK
The secretariat acted purely as support to the panel in the
practical, writing, and dissemination functions and having no say
in the conclusions or recommendations. Further information can
be found in Appendix 1.
3. THE EFFECT OF BREAST SCREENING ON MORTALITY
This section summarises the panel’s views of the effect of breast
screening on mortality. Specifically, the aim is to estimate the effect of
the current national screening programmes in the United Kingdom
on breast cancer mortality. Estimates of relative risk reduction,
absolute risk reduction, and increase in life expectancy are discussed.
3.1 Introduction
Randomised controlled trials potentially provide the most reliable
information about the effects of breast screening. Well-conducted
RCTs are prone to fewer distorting effects, or biases, than
observational studies. Systematic reviews and meta-analyses of
RCTs are widely accepted as the highest level of evidence for
guiding policy decisions on medical interventions. For this reason,
our quantitative estimate of the benefits of breast screening comes
from the randomised trials of breast screening. Given the wealth of
observational studies on this issue, in section 3.6 we look to
observational studies as a possible guide to more contemporary
estimates of the effects of screening on mortality.
Randomised controlled trials, however, are not without their
problems in practice. Lack of internal validity, for example, through
failures in proper randomisation, losses to follow-up and misclassifica-
tion of end points, can lead to biased estimates of effects. Differences
between the trials and the current UK context, for example, in the type
of screening undertaken or in the length of follow-up, lead to a lack of
external validity. Both the internal and external validity of the RCTs of
breast screening have been widely discussed.
A specific issue raised by some commentators is that most of the
randomised trials of breast screening date from the 1980s or
earlier. Treatment and overall management of breast cancer have
improved considerably since that time. Are the trials still relevant?
Such a question can be asked of any area of medical investigation
and treatment; trials refer to the past and our use of interventions
relates to the future. It is an important area of judgement and one
that the panel kept at the forefront of its consideration.
The purpose of screening is to prolong survival, but length of
survival from diagnosis of breast cancer to death cannot be used as an
end point in the RCTs, because the cancers diagnosed by screening are
diagnosed earlier than those diagnosed without screening. Thus, even
in the absence of any therapy, a cancer diagnosed earlier by screening
will have a better survival than the same cancer presenting later
symptomatically. Mortality after invitation to screening is the
appropriate end point. However, concerns have been raised about
the use of breast cancer mortality. If the adjudication of a death as due
to breast cancer is influenced by the woman’s screening history, then
the estimate of the effects on breast cancer mortality can become
biased. For this reason, some have argued that death from all cancers,
or indeed all-cause mortality, should be the primary outcome of
interest in the trials. The panel disagrees with this view (section 3.5).
We also comment on the estimation of absolute risk differences, as
opposed to RRs, and the difference between the effects expressed per
woman invited and per woman screened.
The panel’s view is that although the trials are far from perfect,
they offer the most reliable evidence on the RR reduction in breast
cancer mortality to be derived from screening.
Report BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.177 2209
3.2 Available randomised trials
Eleven randomised trials have been undertaken and reported (New
York health insurance plan (HIP), Malmo¨ I and II, Swedish Two
County (Kopparberg and O¨stergo¨tland), Canada I and II, Stock-
holm, Go¨teborg, UK Age trial, and Edinburgh; Table 1). The three
trials with two parts have sometimes but not always been reported
separately in publications. Three other randomised trials are
mentioned in the Cochrane Review (Gøtzsche and Nielsen, 2011),
but were excluded because they compared multiple interventions (not
just mammography), or made major post-randomisation exclusions.
We also exclude these three studies from our assessment.
All the trials compared women invited to screening with a
control group not invited. However, they varied considerably, for
example, in terms of the method of randomisation, age group of
women invited, type of mammography employed, whether
physical examination or self-examination was also used in either
the invited or control groups, interval between screens, number of
screens, length of follow-up, and system used for adjudicating
breast cancer deaths (Table 1).
Randomisation
The invited and control groups in the trials were constructed either
by randomising individuals, or by randomising clusters (geographical
areas or general practices), or by allocation according to day of birth.
Individual randomisation, with adequate allocation concealment, is
rightly regarded as the most reliable method. For population
screening studies, however, cluster randomisation can also be
adequate, provided sufficient clusters are randomised and balance
in social and other characteristics is achieved. Women are identified
through existing registers, and so it is unlikely that participation bias,
which afflicts some cluster trials (Puffer et al, 2003), would apply (for
example, through women moving between areas in order to avoid or
obtain an invitation to breast screening). Similarly, using allocation
by day of birth would seem to be adequate for population screening
trials. Of the trials considered, the Edinburgh trial suffered the most
problems in terms of its cluster randomisation (Gøtzsche and
Nielsen, 2011), with some re-allocations and post-randomisation
exclusions of clusters, which led to severe baseline imbalances (26%
of women in the control group and 53% in the invited group were in
the highest socioeconomic group). For this reason, like the Cochrane
Review, we exclude the Edinburgh trial from our main summary and
comment on its results separately (section 3.5).
Age
The trials recruited women of different ages (Table 1). Most
overlapped extensively with the age group 50–70 years, relevant to
Table 1. Characteristics of the randomised trials of breast cancer screening
New York
HIP
Malmo¨
I and II
Swedish Two
County
Canada
I and II Stockholm Go¨teborg
UK Age
trial Edinburgh
Start date 1963 1976 1977 1980 1981 1982 1991 1978
Randomisation method Individual Individual Cluster Individual Day of birth Day of
birtha
Individual Cluster
Population of women
Source IC P P Variousb P P PC PC
Number of womenc
(clusters)
62 000 60076 133 065 (45) 89 835 60800 52 222 160 921 54654 (87)
Age group (years) 40–64 45–69 & 43–49 38–75 40–49 & 50–59 39–65 39–59 39–41 45–64
Invited group
intervention
M & PE M M & SE M & PE & SE M M M M & PE
Mammography
No. of views 2 2 then 1/2 1 2 1 2 then 1 2 then 1 2 then 1
Screening interval 12 months 18–24 months 24–33 months 12 months 24–28 months 18 months 12 months 24 months
No. of screening rounds 4 6–8 2–4 4-5 2 4-5 8–10 2–4
Duration of screening 3 years 12 years 7 years 5 years 4 years 7 years 8 years 6 years
Attendance rate 65% 74% 85% 88% 82% 84% 81% 65%
Control group
intervention
None None None PE & SEd None None None None
Follow-up
Controls invited for
screeninge
Not known Neverf After 7y Never After 4y After 7y After 10y After 10y
Cause of death
determination
L IEC, NS L, IEC, NS IEC, NS IES, NS NS NS NS
Abbreviations: HIP¼ health insurance plan; IC¼ insurance company register; IEC¼ independent endpoint committee; L¼ local; M¼mammography; NS¼ national statistics/register;
P¼population register; PC¼primary care register; PE¼physical examination; SE¼ self-examination. Information taken from various publications, but principally the Cochrane Review
(Gøtzsche and Nielsen, 2011; Nystro¨m et al, 2002; Ta´bar et al, 2011). These summaries are sometimes simplifications of characteristics which differ between sub-trials or subgroups. There are
also some discrepancies between different publications.
aDay of birth, and later individual.
bIncludes P, IC, employee recruitment, and general publicity. Women were randomised after initial PE, and there is evidence that the women attending had a higher rate of breast cancer at that
initial attendance than was expected from an age-matched population.
cSome of these numbers are approximate, as different numbers appear in different publications.
dAfter the initial assessment, only the women in Canada II underwent systematic PE during the screening period—in Canada I, they were taught how to do a physical examination.
eSystematic invitation of all controls.
fApplies to Malmo¨ I ages 55–69.
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the UK programmes, but some (e.g. UK Age trial, Malmo¨ II) did
not. We base our primary conclusions about RR on all the trials, as
this appears fairly constant across age groups (Nystro¨m et al,
2002). There is some evidence, however, that the RR may be
attenuated in women under age 50 (Canadian Task Force on
Preventive Health Care, 2011), so we also consider an analysis that
excludes these women.
Duration of follow-up
Even in the pre-screening era, the median survival from diagnosis
of breast cancer was several years, so any benefits of screening in
terms of mortality are not immediate, but will accrue over time.
So the best evidence would come from a trial with a long duration
of follow-up, comparing the invited group with a control group
who are never invited to screening. The data that come nearest
to this are for the age group 55–69 in Malmo¨ I, with a follow-up
of 19 years. Most of the trials, however, started systematic
screening of the control group after 4–10 years. Little effect on
mortality is seen within the first 5 years of screening, so we regard
a follow-up period of about 10–15 years after randomisation as
providing the most reliable estimate of the RR. A shorter follow-up
time would put too much weight on the early period after initial
screening, whereas a longer period would include a greater
diluting effect of screening in the control group. So we base our
primary conclusions about breast cancer mortality on the data
reported in the Cochrane Review, which provided results for 13
years of follow-up of the groups as randomised (Gøtzsche and
Nielsen, 2011).
Adjudicating cause of death
Potential biases from classifying cause of death have been a major
source of contention, especially in the Swedish trials. Ascribing a
death as primarily due to breast cancer, or not due to breast cancer,
is not always easy or reliable. So, when the screening history of a
woman is known, or when a prior diagnosis of breast cancer has
been made, this could influence the adjudicated cause of death.
There are two ways in which this could distort the results of the
trials. The first is overt bias, in which investigators closely involved
with the trial adjudicate cause of death and tend to avoid ascribing
the cause of death as breast cancer when the woman has been
screened (and conversely if they had not). This would exaggerate
any beneficial effect of screening. This bias (which may be
subconscious) is avoided by the use of an independent end point
committee to ascribe causes of death, or by the use of death
certificates from national registries. These methods however do not
avoid a second way in which a trial’s results might be affected;
screening increases the number of breast cancers diagnosed,
and such a diagnosis may lead preferentially to classifying a
subsequent death as due to breast cancer rather than any other
cause. This second bias operates against any beneficial effect of
screening.
Most trials used an independent end point committee to
adjudicate causes of death or took the underlying cause of death
from national registries (Table 1). Some of the Swedish trials were
criticised for using trial investigators to ascribe cause of death, but
subsequent evaluations were made using independent and
consensus committees and national registry statistics (Nystro¨m
et al, 2002; Ta´bar et al, 2011). Although the exact numbers of
deaths from breast cancer were not the same when adjudication
was made using different methods, the overall estimates of RR
of breast cancer mortality did not change very much. Thus,
although this issue is certainly one of the major criticisms of the
trials, the panel does not think it would exaggerate the estimates of
RR reduction obtained from individual trials, or indeed from a
meta-analysis of trials. We comment on the use of other mortality
end points in section 3.5.
Other issues
Many other aspects of the trials have been discussed in the
literature, some of which we mention here. The numbers of women
reported in each randomised group have not been identical
across the multiple publications from certain trials. Although
this is somewhat concerning, it is perhaps not surprising,
given that population and other registers are not always fully
reliable, and data checks over time reveal duplicates and other
problems. Moreover, some publications are based on birth
cohorts and others on exact age groups (Nystro¨m et al, 2002).
The trials report excluding women with a prior diagnosis of
breast cancer. Although this is sensible, it can lead to problems if
the exclusions are more easily made in the invited group (for
example, because of more information obtained at screening) than
in the control group. Some trials include physical examination or
self-examination in either or both of the randomised groups.
However, there is no evidence that these procedures influence
breast cancer mortality (Canadian Task Force on Preventive
Health Care, 2011).
Conclusion
We acknowledge the problems and biases discussed above,
but judge them as unlikely to have had a major distorting
effect on the overall result from a meta-analysis of the trials.
Moreover, the biases considered do not all operate in the same
direction, with some favouring screening and some acting against
it. Although it is easy to be critical of many detailed aspects of the
breast screening trials, the relevant judgement is whether the biases
are so great as to make their results too misleading for guiding
policy. The panel does not believe this to be the case, especially in
contrast to the problems in interpreting the results from
observational studies (section 3.6).
3.3 Meta-analysis of RRs
As discussed above, we focus on the deaths ascribed to breast
cancer in 10 of the 11 randomised trials (excluding Edinburgh) and
the meta-analysis conducted in the Cochrane Review, using 13
years of follow-up (analysis 1.2 in Gøtzsche and Nielsen, 2011). We
do not distinguish the trials labelled ‘adequately randomised’ and
‘sub-optimally randomised’ in the Cochrane Review, but consider
the totality of evidence across all the trials. We also use random-
effects rather than fixed-effect meta-analysis to estimate an average
effect across the trials. Using random effects acknowledges that
the trials may be estimating different quantities, which is likely
given their clinical heterogeneity, whereas a fixed-effect analysis
estimates an assumed common effect across all the trials.
The results are shown in Figure 2 along with the RRs of breast
cancer mortality. The overall RR, comparing invited with control
women, is 0.80 (95% CI 0.73–0.89). There was some heterogeneity
in the RRs from different trials, but this was not statistically
significant (Figure 2). Thus, the RR reduction in breast cancer
mortality in the groups invited to screening is estimated as 20%
(95% CI 11–27%).
The RR for women invited to screening is attenuated compared
with that for women who actually attend screening (Cuzick et al,
1997). This is because some invited women do not attend, and they
may be assumed to get no benefit from the invitation. If the
underlying rate of breast cancer mortality in non-attenders is the
same as in attenders, one may estimate the RR reduction in
attenders as the RR reduction in those invited divided by the
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(average) attendance rate. Taking the typical attendance in the trials as
about 80% (Table 1), this would give 20% divided by 0.80, or 25%).
However, this calculation is incorrect as the underlying risk is
different in those not attending screening (Zackrisson et al, 2004;
Moss et al, 2006). Without this extra information, which is not
available for all trials, the calculation of the RR reduction in those
attending screening is not possible. In contrast, the calculation can be
made, irrespective of underlying risk differences, for the absolute risk
reduction (section 3.4). We note that the coverage rate in the UK
NHS screening programme is similar to that in the trials, at 77% (The
NHS Information Centre, Public Health Indicators Team, 2011).
Some non-systematic (opportunistic) screening occurred in the
control groups of the trials, but detailed information is not available.
This is ignored in our calculations, and will lead to the effect of
attending screening being somewhat underestimated.
Other estimates of overall RR
Other meta-analyses of the breast cancer screening trials have
given different estimates of the RR reduction. We summarise some
of these below.
 The Cochrane Review undertook a fixed-effect meta-analysis of
the above trials with 13 years follow-up, and reported an
estimated RR of 0.81 (95% CI 0.74–0.87). As expected, the fixed-
effect analysis gives a slightly narrower CI, but the estimated
average RR reduction of 19% is similar to the figure of 20%
above.
 If womeno50 years in the above trials are excluded, the overall
RR reported in the Cochrane Review (analysis 1.6, Gøtzsche and
Nielsen, 2011) is 0.77 (95% CI 0.69–0.86). So the RR reduction is
estimated as 23%, slightly more than the 20% above based on all
age groups.
 The Cochrane Review (Gøtzsche and Nielsen, 2011) focused on
the Canada, Malmo¨, and UK Age trials as the only ‘adequately
randomised’ trials. The estimated RR of breast cancer mortality
over 13 years follow-up for invited vs control groups in these
trials was 0.90 (95% CI 0.79–1.02), whereas in the trials
considered ‘sub-optimally randomised’ it was 0.75 (0.67–0.83).
As a compromise between these two estimates, the authors
concluded that a 15% RR reduction was plausible.
 The US Task Force (Nelson et al, 2009) provided estimated RRs
of breast cancer mortality of 0.86 (95% CI 0.75–0.99) for women
aged 50–59 years invited to screening, and of 0.68 (95% CI
0.54–0.87) for those aged 60–69 years. These correspond to RR
reductions of 14% and 32%, respectively, with an inverse
variance weighted average of 19%.
 The Canadian Task Force (Canadian Task Force on Preventive
Health Care, 2011) gave an estimate of the RR of breast cancer
mortality for invited vs control groups of 0.79 (95% CI 0.68–0.90)
for women aged 50–69 years, a RR reduction of 21%. Routinely
screening for breast cancer with mammography every 2–3 years for
this age group was rated as a weak recommendation, based on
moderate-quality evidence according to GRADE criteria
(Schu¨nemann et al, 2011).
 A review by Duffy et al (2012) of all the trials and age groups
gave an overall RR of 0.79 (95% CI 0.73–0.86) comparing invited
with control groups, corresponding to a 21% RR reduction in
breast cancer mortality.
Different meta-analyses include different trials, durations of follow-
up, and definitions of outcome. Nevertheless, there is general
agreement in their estimates, of about a 20% RR reduction in breast
cancer mortality from invitation to screening.
Generalisability of RRs
A key issue is whether the RR reduction in breast cancer mortality
observed in the trials may be taken as applying, at least
approximately, to the current UK screening programmes. This is
a judgement about external validity, rather than an issue for which
much direct empirical evidence is available. As always in policy
decision making, we need to use evidence from studies undertaken
in the past to make an inference about what is likely in the future.
Although RRs are often much more generalisable across contexts
than absolute risk differences, it is clearly plausible that RRs could
change in new situations. Of particular concern in breast screening
is that many of the trials were undertaken a long time ago, that the
techniques of mammography have changed considerably, that
DCIS is now commonly diagnosed through screening (section 4.6),
that the treatments for breast cancer, particularly the drug
treatment that can eradicate microscopic spread, have become
Study
ID
Relative risk
(RR) (95% Cl)
Weight
(%)
New York (1963) 0.83 (0.70, 1.00) 16.9
9.5
10.7
13.0
10.2
10.2
6.0
10.7
12.8
0.81 (0.61, 1.07)
0.58 (0.45, 0.76)
0.76 (0.61, 0.95)
0.97 (0.74, 1.27)
1.02 (0.78, 1.33)
0.73 (0.50, 1.06)
0.75 (0.58, 0.98)
0.83 (0.66, 1.04)
0.80 (0.73, 0.89)
0.5 0.8
Relative risk
1 1.25 1.5
Malmö I (1976)
Kopparberg (1977)
Ostergötland (1978)
Canada I (1980)
Canada II (1980)
Stockholm (1981)
Göteborg (1982)
UK age trial (1991)
Overall (I2= 31.7%, P = 0.164)
NOTE: Weights are from random-effects analysis
Figure 2. Meta-analysis of the breast cancer screening trials: RR of breast cancer mortality after 13 years of follow-up. Adapted from the
Cochrane Review (Gøtzsche and Nielsen, 2011). Note: Malmo¨ II is excluded because follow-up approximating 13 years was not available; the
Swedish Two County (Kopparberg and O¨stergo¨tland) and Canada I and II trials are split into their component parts; the Edinburgh trial is excluded
because of severe imbalances between randomised groups.
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more effective, and that the overall mortality rate from breast cancer
has decreased in the United Kingdom and other countries. These
points were put to the panel by some expert witnesses. One could
therefore argue that breast screening is now less effective/relevant
because even later stage cancers can be treated and/or cured, so there
is less need to diagnose breast cancers earlier. However, there is a
counter argument that because the systemic drug treatments are only
partially effective, it could be that the major improvements that drug
treatments have brought in cure rates are in fact in part due to breast
screening: by diagnosing more cancers at an earlier stage,
contemporary drug treatments have a better chance of eradicating
microscopic disease, and thus the gains in survival would not have
been as great if breast screening did not exist.
Both views have some supporting arguments, but the panel found
no convincing evidence that one or other was more likely
to be correct. Thus, the panel’s view is that the appropriate
manner in which to view the benefits of screening and those of
better treatments are that these effects are independent, and
thus that the estimates of the relative reduction in breast
cancer mortality achieved with screening are the same now as 20
years ago. However, the uncertainty about whether there could be an
interaction between the benefits of screening and of contemporary
treatments is not a reason for stopping breast screening.
Particular aspects for which there is at least some evidence about
the external validity of the trials relate to age, screening intensity,
and follow-up time. The RR does not appear to change much
across the age range 50–69 years (Nystro¨m et al, 2002), but it may
be reduced below the age of 50 (Canadian Task Force on
Preventive Health Care, 2011). The RR does not appear to depend
strongly on the number of screens, or the screening interval, at
least across the ranges studied in the trials. The only randomised
trial that compared different screening intervals is inconclusive
(Breast Screening Frequency Trial Group, 2002). Reports from
trials with long follow-up suggest that little benefit in terms of
breast cancer mortality is seen in the first 5 years after starting
screening, and that the benefit lasts for at least 10 years after
cessation of screening. This is not surprising, given the slow
progression rates of many breast cancers.
Conclusion
The panel concludes that the current screening programmes in the
United Kingdom, which invite women aged 50–70 every 3 years to
undergo mammography, are likely to deliver about a 20% reduction
in breast cancer mortality at ages 55–79 years. Clearly, there is
uncertainty in this figure. In addition to the uncertainty owing to the
limited numbers of breast cancer deaths across the trials, there are
potential biases in the trials and concerns about the generalisability of
results from the trials to the current UK screening programmes. We
note, however, that the level of disagreement in the literature about
the RR reduction is minor in comparison to the controversy about the
absolute risk reduction.
3.4 Absolute risk reduction
The above discussion suggests a natural way to estimate the
absolute risk reduction that applies to the current screening
programmes in the United Kingdom. For women aged 50
invited to screening, we assume no benefit in breast cancer
mortality until age 55, a 20% reduction at ages 55–79, and
no change in the rates of other causes of death. An estimated
1.70% of UK women aged 50 are currently expected to die from
breast cancer between the ages of 55 and 79; this is calculated
from UK mortality rates (2008–2010) and takes into account the
risks of dying from other causes. Since the UK programme has
existed since the late 1980s, one may assume that this risk has
already been reduced by 20% through screening. Hence, the risk
without the screening programme would have been 2.13% (as 1.70/
2.13¼ 0.80), and the estimated absolute risk reduction is
2.13 1.70¼ 0.43%.
The number of women needed to be invited for screening for 20
years starting at age 50 in order to prevent one death from breast
cancer is therefore 1/0.43%¼ 235. An alternative way of expressing
this is that, for every 10 000 women invited into the screening
programme at age 50, about 43 deaths from breast cancer would be
prevented.
The absolute risk reduction for women attending screening can
be estimated as the absolute risk reduction in those invited divided
by the average coverage rate in the NHS breast screening
programme (77%), so about 0.43%/0.77¼ 0.56%. The number of
women needed to be screened for 20 years to prevent one death
from breast cancer is then 1/0.56%¼ 180. For every 10 000 women
attending screening from age 50–70 years, about 56 deaths from
breast cancer would be prevented.
The above calculations are based on the same principles as those
used in some publications (Advisory Committee on Breast Cancer
Screening, 2006). Essentially, the RR reduction from the trials is
regarded as approximately generalisable to the current UK
screening programmes, and the corresponding absolute risk
reduction is calculated by applying this RR reduction to the
national rates of breast cancer mortality for an appropriate age
group. The considerable uncertainty in the estimated RR reduction
of 20%, as discussed in section 3.3, of course carries through to
these estimates of absolute risk reduction.
The NHS screening programme estimates that 1400 lives are
saved per year in England owing to breast screening (Advisory
Committee on Breast Cancer Screening, 2006). For comparison
and illustrative purposes, the panel estimates that for the 307 000
women (aged 50–52) who each year receive their first invitation to
a 20-year screening programme (3-year average 2008/2009–2010/
2011, The NHS Information Centre, Public Health Indicators
Team, 2011), 0.43% of 307 000, or about 1300, deaths from breast
cancer per year are prevented. This is close to the NHS screening
programme’s estimate.
Different methods and estimates in the literature
The marked difference in estimates of absolute risk reduction
proposed in the literature is one of the greatest sources of
controversy about the value of breast cancer screening
(McPherson, 2010). The different estimates stem from the very
varied methods used for their calculation. When calculations are
made directly from the trials’ data themselves, the absolute risk
reduction depends overwhelmingly on the underlying risk of breast
cancer, which is principally governed by the age groups considered,
the length of follow-up, and the population studied. Although this
is obvious, it has also been empirically shown by comparing
different durations of follow-up in the Swedish Two County trial
(Ta´bar et al, 2011).
 The Cochrane Review (Gøtzsche and Nielsen, 2011) focused
on the Canada, Malmo¨, and UK Age trials as the only ‘adequately
randomised’ trials. The absolute risk of breast cancer death
in the control groups of these trials was low (overall
rate of 0.33%), partly because of the inclusion of the large UK
Age trial (women initially aged 39–41) and the 13-year follow-up
period considered rather than the 25-year period from age 55–79,
used above by the panel. With the Cochrane Review authors’
estimated 15% RR reduction, this leads to an estimated absolute risk
reduction of 0.05%, or equivalently that 2000 women need to be
invited to screening to prevent one breast cancer death.
 An entirely different estimate is given by Duffy et al (2010) based
on 22 years of follow-up for those aged 50–69 in the Swedish
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Two County trial, which estimated a 38% reduction in breast
cancer mortality. The calculation considers the absolute risk
reduction per women screened across the 7 years of screening in
the trial, and makes the strong assumption that the absolute
benefits can simply be multiplied up to reflect the 20 years of
screening in the UK programmes. This leads to an estimated
absolute risk reduction of 0.88% in women screened, or
equivalently that 113 women need to be screened to prevent
one breast cancer death.
 The US Task Force (Nelson et al, 2009) considered a period of
7 years of invitation to screening and 13 years of follow-up after
first invitation (Nelson et al, 2009). For ages 50–59 years, they
estimated that 1339 women needed to be invited to prevent one
death from breast cancer. For ages 60–69 years, their
corresponding estimate was 377 women.
 The Canadian Task Force (Canadian Task Force on Preventive
Health Care, 2011) estimated from the trials that screening 720
women aged 50–69 years once every 2–3 years for about 11 years
would prevent one death from breast cancer.
 Beral et al (2011) summarised various published estimates of
absolute risk reduction from the literature, and concluded that
around one breast cancer death would be prevented in the long
term for every 400 women aged 50–70 years regularly screened
over a 10-year period, based on a previous review (Advisory
Committee on Breast Cancer Screening, 2006).
From the above examples, it is clear that different methods of
estimation give about a 20-fold difference in the estimates of absolute
risk reduction. The panel’s view is that to estimate the impact of the
UK screening programmes on absolute risk of dying of breast cancer,
it is necessary to consider the relevant underlying risk of breast cancer
to which the RR reduction from the trials should apply. The panel
believes this is best derived from the current UK national rate of
breast cancer deaths for women aged 55–79 years. Calculations made
directly from the absolute risks observed in the trials are heavily, and
often misleadingly, influenced by the age groups included and the
length of follow-up available (Beral et al, 2011). Estimates also depend
on whether they are expressed per woman invited or per woman
screened. We note, however, to the extent that the absolute rate of
breast cancer mortality in the United Kingdom is currently declining,
the absolute risk reduction from the UK screening programme would
also be expected to decline correspondingly in the future.
Life expectancy gained
A reduction in the risk of breast cancer will lead to an increase in life
expectancy. As breast cancer is only one of many causes of death, the
average gain in life expectancy from the UK screening programme is
likely to appear modest. An estimate can easily be derived by
contrasting the life expectancy for women aged 50, using current
national rates of breast cancer mortality and deaths from other causes,
to that which would apply if the rates of breast cancer mortality were
25% higher in each year from age 55–79 years. (25% higher
corresponds to the assumed 20% benefit from screening, as 1.25¼ 1/
0.80.) This calculation leads to an estimate of 0.073 years (or 27 days)
of life gained on average for each woman aged 50 invited to screening.
To put this in perspective, the panel noted that abolition of all deaths
from breast cancer completely would add 159 days on average to life
expectancy for women aged 50.
We also note that this is a crude average of a zero gain for the
vast majority of women and a substantial gain for a few.
Alternative but equivalent ways of expressing this gain are as
follows: (a) for the 307 000 women aged 50–52 who are invited for
screening each year, about 22 000 years of life will be saved; (b) for
each 10 000 women invited to screening, 730 years of life will be
saved; (c) for each 10 000 attending screening, about 950 years of
life will be saved; (d) given that 1 in about 180 women attending
screening avoid breast cancer death, such a woman would expect to
gain on average an extra 17 years of life.
3.5 Other considerations
Edinburgh trial
The Edinburgh trial was the only UK trial in an age group that is
within that of the national screening programme. However, as
discussed in section 3.2, we excluded this trial because problems in
the cluster randomisation led to a severe imbalance in socio-
economic status of the women between the groups, and socio-
economic status influences, in opposite directions, the risk of
developing breast cancer and of dying from breast cancer. At 14
years of follow-up, the unadjusted results showed a 13% reduction
in breast cancer mortality. However, on adjusting for socio-
economic status, the rate ratio was 0.79 (95% CI 0.60–1.02), a RR
reduction of 21% (Alexander et al, 1999). Thus, although doubts
must remain about the validity of this latter estimate, we note that
it very much in line with the figure of 20% we have used above.
Other outcomes
In the preceding sections, we have focused exclusively on breast
cancer mortality. Owing to the concerns about whether such
deaths are reliably adjudicated in the trials, some authors have
suggested that this has led to exaggerated estimates of the RR
reduction, and that the outcomes of death from any cancer, or
death from any cause, are the appropriate ones for judging the
impact of breast screening on mortality. The panel disagrees with
this: evaluating all-cancer or all-cause deaths in the trials will lack
power because breast cancer deaths represent only a small
proportion within these categories. In particular, a 20% RR
reduction in breast cancer deaths for ages 55–79 years would yield
only 3.0% and 1.2% RR reductions in all-cancer and all-cause
deaths, respectively. The trials are not of sufficient size (in terms of
numbers of women and length of follow-up) to allow such small
RR reductions to be reliably estimated. Hence, a statistically non-
significant effect for all-cancer or all-cause deaths in the trials
cannot be interpreted as evidence against a reduction in breast
cancer deaths.
Some authors have argued that changes in the incidence of more
advanced breast cancer, whether defined as above a certain tumour
size or with spread to the ipsilateral axillary nodes, is a useful
surrogate indicator of the effect of screening on breast cancer
mortality in the trials, as the ultimate risk of dying of breast cancer
depends in part on the stage of disease at first presentation.
Although, on average, one could expect a breast cancer screening
programme to lead to diagnosis of breast cancers at an earlier stage,
this approach cannot, however, directly exclude lead time effects.
The situation is further complicated by the issue of interval
cancers, which have been shown in more than one study, as
compared with screen-detected cancers, to be more often high
grade, which is itself predictive of a poorer prognosis. However,
what is less clear is whether the prognosis of a breast cancer is
determined only by the stage when diagnosed, or whether in the
absence of a screening programme the underlying biology is the
main determinant of outcome, and this in turn influences when the
cancers present. Thus, for those cancers diagnosed earlier by
screening, it is not clear which, if any, of the clinical markers of
prognosis (stage, size, grade etc.) is the best predictor of ultimate
outcome; or is it some other fundamental characteristic only
assessable by molecular biology?
Therefore, there appears to be little reason to use these surrogate
outcomes as evidence for or against the benefits of screening, as
substantial assumptions are needed to estimate the consequent effect
on breast cancer mortality. Only if one wanted to disregard
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completely the evidence about breast cancer mortality from the trials,
would the use of such surrogate outcomes have value.
There are possibilities of specific harms of screening in terms of
induction of other cancers through the X–rays used in mammo-
graphy or the radiotherapy or drug therapy used to treat breast
cancer, and of coronary damage and deaths through radiotherapy
(especially of the left breast). These potential harms are discussed
in section 5.2.
Statistical and other uncertainties
It is conventional that results from statistical analyses, including
meta-analyses, are presented with a measure of statistical
uncertainty such as 95% confidence limits. Although these are
helpful in giving an impression of the possible influence of the play
of chance (given the sample sizes that are available in the studies
considered), they fail to represent the uncertainties because of
possible biases (from lack of internal validity of the studies) or
owing to generalisation from the trials to a new context (external
validity). So, the CI given for the RR reduction of breast cancer
mortality from a meta-analysis of the trials is an understatement of
the uncertainty about the RR reduction that applies to the UK
screening programmes. A RR reduction of 20% represents the
panel’s judgement of the evidence, and should be regarded as an
approximate figure rather than a precise estimate.
3.6 Observational studies
In addition to the trials, the panel also considered the value of
observational studies in estimating the impact of screening on
breast cancer mortality. The RCTs of mammographic screening
were conducted at least 20 years ago and most over 30 years ago.
Observational studies may help to quantify the effects of screening
in an era with major improvements in diagnostic imaging, clinical
care, and patient outcomes, as many of the observational studies
are more recent than the trials. Both proponents and critics of
screening have suggested that the observational studies are more
relevant today than the RCTs. However, these studies are beset by
many more biases with consequent problems of interpretation. It is
also possible that they are more prone to selective reporting than
trials, in that the results obtained determine the enthusiasm of the
authors and journals for publication.
The biases inherent in observational studies differ by type of
study. All share the common problem of potential lack of
comparability of screened and unscreened women. It is this
feature that the RCTs are designed to address. Each observational
study design has strengths and weaknesses and, within each class,
specific studies vary in their methods and credibility. The relative
merits and problems of the various observational study designs are
hotly contested both in the literature and in the evidence the panel
heard.
Ecological and time-trend studies
Some observational studies compare time trends for breast
cancer mortality in countries or areas before and after the
introduction of screening, or concurrently between areas with
and without screening. In the first type of study, extrapolation of
time trends demands that decisions are made, for example, about
the linearity or otherwise of the trend, the choice of time periods
considered as ‘before’ and ‘after’ screening, and the age groups
included. In the second type of study, choices have to be made
about the areas to include, the time period considered, and the age
groups included. Such decisions, which can appear to have been
made rather arbitrarily, can have a profound impact on the estimates
obtained. Lack of comparability and different time trends in the
groups being contrasted could lead to substantial bias. For these
reasons the panel does not consider that these types of studies
provide reliable evidence on the effect of screening on breast cancer
mortality, and amongst observational study designs we focus instead
on case–control studies and incidence-based mortality studies.
Case–control studies
Case–control studies compare the history of breast screening
attendance between women dying of breast cancer and control
women who did not die of breast cancer. Case–control studies are
prone to a number of potential biases. The main problem with
case–control studies is that those attending breast screening are
different from those who do not attend. This is referred to as self-
selection bias or the ‘healthy screened effect’. Attendance is
influenced by social and demographical factors that are also likely
to be related to the risk of dying from breast cancer, with the
resulting bias potentially exaggerating the estimated effect of
screening. Also, the existence of a breast screening programme in
an area may be associated with better treatment of breast cancer.
Therefore, women diagnosed with breast cancer in an area with a
breast screening programme may also receive more effective
treatment than women where there is no such programme. This
would bias the study in favour of screening. Attempts are made to
correct for the resulting biases by choice of controls and statistical
adjustment (Connor et al, 2000; Duffy et al, 2002).
Some of the expert witnesses who gave evidence to the panel felt
that case–control studies provided the most reliable form of
observational data while others believed the opposite. The panel
undertook a review of the individual characteristics of a number of
case–control studies to assess the potential bias of each one
(Appendix 3). In general, the studies matched controls to cases by
both age and residence but some matched on just one of these
variables. Self-selection bias was discussed in around three-quarters
of the studies and statistically controlled for, using a variety of
methods, in less than half of the studies (Appendix 3).
The case–control studies show more favourable benefit of
screening compared with the trials. The panel believes that this is
plausibly because of inadequate control for self-selection bias rather
than in screening actually being far more beneficial now than in the
trials. Attempts to correct for self-selection bias were based on
information outside of the study itself (either from a previous time
period, or from other geographical areas) that may not be fully
relevant. When adjustment was made, the apparent benefit of
screening was diminished. The bias that screening could be associated
with better treatment was controlled for studies conducted in
countries with uniform treatment services.
In conclusion, the panel notes that the beneficial effects of
screening are in the same direction as those seen in the trials, but
that control for self-selection bias may be inadequate in many of
the studies.
Incidence-based mortality studies
Njor et al (2012) conducted a review of European studies on the
impact of service mammography screening on breast cancer
mortality using incidence-based mortality. In these studies, only
breast cancer deaths occurring in women with breast cancer
diagnosed after their first invitation to screening are included. They
classified the studies according to type of comparison group. These
were (1) women not yet invited, (2) historical data from the same
region as well as from historical and current data from a region
without screening, and (3) historical comparison group combined
with data for non-participants.
They found that the effect of screening on breast cancer
mortality varied across studies. The RRs were 0.76–0.81 in group 1;
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0.75–0.90 in group 2; and 0.52–0.89 in group 3. Study databases
overlapped in both Swedish and Finnish studies, adjustment for
lead time was not optimal in all studies, and
some studies had various other methodological limitations.
There was less variability in the RRs after allowing for the
methodological shortcomings. On the basis of evidence from the
most reliable incidence-based mortality studies, they concluded
that the most likely impact of European breast screening
programmes was a breast cancer mortality reduction of 26%
(95% CI 13–36%) among women invited for screening and
followed up for 6–11 years.
Conclusion
Many observational studies have been published, and their
conclusions hotly contested. In general, the more contempora-
neous case–control and incidence-based mortality studies support
the evidence from the trials that screening does have a beneficial
effect on mortality. The panel’s view is that the trials provide more
reliable evidence for an estimate of mortality reduction. Never-
theless, the observational studies support the hypothesis that
screening continues to be beneficial in an era of improved
treatment.
4. OVERDIAGNOSIS
4.1 Introduction
The purpose of breast screening is to detect cancer early, before it
has come to clinical attention. If all cancers would eventually be
clinically recognised and treatment was the same and equally
effective no matter when the tumour was diagnosed, then screening
would be redundant. However, the understanding is that if the
cancer is diagnosed earlier, then treatment will be more effective.
This is the assumption on which screening is based. The evidence
reviewed in section 3 supports that assumption.
As cancers are detected earlier because of screening, we expect
the cancer incidence to be higher among screened women during
the screening period (the time period between the detection of a
cancer at screening and when it would have presented clinically is
the ‘lead time’ and is an inevitable part of screening). In principle,
when screening ceases the incidence should fall back so that by the
end of the screening period plus lead time, the cumulative
incidence in the screened and control populations should be the
same.
Some screen-detected cancers, however, may never progress to
become symptomatic (clinically detectable) while some women
would die from another cause before the cancer became evident.
This adverse consequence (harm) of screening is called over-
diagnosis or overdetection. It is variously defined as the ‘detection
of cancers on screening that would not have been found were it not
for the screening test’ (IARC, 2002), or ‘that would never have
clinically surfaced in the absence of screening’ (Seigneurin et al,
2011) or ‘that would not have presented clinically during the
woman’s lifetime (and therefore would not have been diagnosed in
the absence of screening)’ (Biesheuvel et al, 2007). Thus, it refers to
all cancers, invasive or in situ.
Underpinning the concept of overdiagnosis is the belief that
cancers grow at variable rates, as depicted, for example, in Figure 3A
(Esserman et al, 2009; Elmore and Fletcher, 2012). Some screen-
detected cancers may progress so slowly, that they would never have
presented clinically; theoretically, some may be static or even regress
but the practical effect is the same. Detection of these cancers turns
women into patients, leads to surgery and other treatments that by
definition are not beneficial for these women and can cause harm,
and adversely affects their quality of life.
As cancers are diagnosed earlier owing to screening, we expect
cancer incidence to be higher among screened than unscreened
women during the screening period. However, when screening
ceases, the incidence should fall back (sometimes referred to as the
compensatory drop). If there is no overdiagnosis, the cumulative
incidence in the screened and unscreened women will equalise
after screening ceases, after a period equivalent to the lead time has
elapsed. (Figure 3B, left). If there is overdiagnosis, however, the
cumulative incidence will remain higher in the screened group and
not equalise over time (Figure 3B, right).
Some overdiagnosis is seen as inevitable – some women will die
before their screen-detected cancer would have presented sympto-
matically. Establishing its frequency is critically important in
weighing up the benefits and harms of screening, both for popula-
tions and individual women. A big challenge is to get unbiased
estimates of the risk. Opinions on the frequency of overdiagnosis
range from it being trivial and unimportant to women to being very
important and swamping any benefit of screening.
Whether a particular woman has had an overdiagnosed cancer,
or whether individual tumours are overdiagnosed, cannot be
judged. It is only possible to estimate frequency of overdiagnosis.
The issue for the UK screening programmes is the magnitude of
overdiagnosis in women who have been in a screening programme
from age 50–70, then followed for the rest of their lives. There are
no data to answer this question. Any estimate will therefore be, at
best, provisional.
4.2 Sources of data on overdiagnosis
Overdiagnosis can be estimated from RCTs or observational studies.
Valid estimates depend on similar underlying risks of breast cancer
in the screened and unscreened women, and that the effect of lead
time has been accounted for (Puliti et al, 2012). Overdiagnosed
cancers are not all those detected earlier by screening but the subset
that would not otherwise have been detected at all.
Randomised controlled trials have the advantage that by design
they compare groups of women with the same average prognosis.
There are disadvantages of the available RCTs though, including a
screening phase that was always shorter than that employed in the
NHS national screening programmes, and which varies across the
RCTs.
The most reliable estimates of overdiagnosis are from those
RCTs in which there was no screening of the control group at the
end of the screening period. As screening advances detection of
breast cancer, follow-up should extend beyond the screening
period to allow a catch up of diagnoses in the unscreened group. In
essence, this extended follow-up is needed to distinguish earlier
diagnosis from overdiagnosis. If allowance is not made for such
catch up, the extra cancers diagnosed in the screened group include
some that would also have emerged without screening, albeit later.
In principle, the extended period of follow-up should correspond
to the lead time, but the average lead time is also the subject of
debate, and the lead time is not the same for all cancers. As follow-
up is extended well beyond the screening period, new cancers in
both the screened and unscreened groups will be included
regardless of screening, and the ratio of total numbers of
diagnosed cancers will converge towards one (Puliti et al, 2012).
An ideal follow-up would be to the end of women’s lives.
However, pragmatically an adequate follow-up is perhaps 5–10
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years after the end of the intervention period (Biesheuvel et al,
2007; Puliti et al, 2011). The trials that clearly did not invite
the control group for screening at the end of the screening
phase were the two Canadian trials and the Malmo¨ I trial
for women aged 55–69 years (Miller et al, 2000, 2002; Zackrisson
et al, 2006).
In the other RCTs, all the women in the control group were
offered screening at the end of the active period of the trial.
Estimates of overdiagnosis from these trials are problematic.
Screening of women in the control group might itself be expected
to lead to some overdiagnosis, and thus to an overall underestimate
of overdiagnosis. Exclusion of cancers diagnosed at the end-of-trial
screening of the control group would overestimate overdiagnosis, as
the control women have not been followed long enough.
Besides the RCTs, there are many non-randomised (observa-
tional) studies that have attempted to estimate overdiagnosis.
These studies raise many concerns, according to the study design,
with the key concern being the likely non-comparability of groups,
for example, in different geographical areas. As one contributor to
overdiagnosis is the development of other diseases leading to death,
the risk of overdiagnosis might be age-dependent. Estimates of
overdiagnosis may thus be affected by the age distribution of the
screened group. For non-RCTs it is especially important that age
distributions are comparable.
4.3 Estimating overdiagnosis
Overdiagnosis can be estimated by comparing the incidence of
breast cancer in cohorts of screened and unscreened women who
were followed for several years. Unfortunately, although there is
agreement on the concept of overdiagnosis, there has been a wide
divergence of views on how to estimate the amount of over-
diagnosis, with the result that estimates of the frequency of
overdiagnosis vary widely, from B 0–50%.
The estimated amount of overdiagnosis depends greatly on the
way the calculation is made, and many different methods exist. De
Gelder et al (2011) (Appendix 4) described seven approaches, all of
which have been applied in recent publications. The differences
relate to which cases are included in the numerator and,
especially, on the choice of denominator. The rate of over-
diagnosis can be considered in relation to women invited to be
screened, women actually screened, or cancers actually detected
by screening. It can also relate to lifetime or the screening age
range. It can be expressed as a percentage of the cancers
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Figure 3. (A) Varying screen detection capability in relation to tumour growth rate (copied from Esserman et al, 2009). (B) Hypothetical cumulative
incidence of breast cancer without (left) or with (right) overdiagnosis based on screening women between 50–68 years (copied from Biesheuvel
et al, 2007; red line shows screened women and blue line unscreened women). (C) Meta-analysis of estimates of overdiagnosis: (a) excess cancers
as a proportion of cancers diagnosed over whole follow-up period in women invited for screening, (b): excess cancers as a proportion of cancers
diagnosed during screening period in women invited for screening. (D) Consequences of overdiagnosis.
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diagnosed in the screening group or as the percentage excess over
that seen in the unscreened group. Also, it can be expressed as a
relative increase or an absolute increase. Clearly, the different
estimates address different questions. Understanding published
estimates of overdiagnosis percentages requires identification of
exactly how those estimates were derived.
The panel believes that there is no single best way to estimate
overdiagnosis. For RCTs, the main options are:
 From the population perspective, the proportion of all cancers
diagnosed during the screening period and for the rest of the
woman’s lifetime in women invited to screening who are over-
diagnosed (not including any diagnosed before the age of screening).
This probability can be estimated using the difference in cumulative
numbers of newly diagnosed breast cancers in groups invited or
not invited to be screened, expressed either as a percentage of
the number of cancers in the control group (excess risk) or as a
percentage of the number of cancers in the screening group
(proportional risk). This probability will diminish over time as the
number of newly diagnosed cancers increases in both groups.
 From the perspective of a woman invited to be screened, the
probability that a cancer diagnosed during the screening period
represents overdiagnosis (Welch et al, 2006; Harris et al, 2011).
This probability can be estimated using the difference in
cumulative numbers of newly diagnosed breast cancers in groups
invited or not invited to be screened, expressed as a percentage of
the cancers diagnosed during the screening phase of the trial for
women in the invited group. The cases in the invited group can
also be restricted to those actually detected at a screening visit –
that is, excluding interval cancers or cancers among women who
did not attend for screening.
These approaches use the same numerator but varying denomi-
nators. The panel considers that the appropriate calculations should
include DCIS cases, but notes that some studies have reported
estimates of overdiagnosis in relation to invasive cancers only.
The panel illustrates how different approaches yield various
estimates using data from the Malmo¨ trial (Andersson et al, 1988;
Zackrisson et al, 2006), partly following Welch (Welch et al, 2006;
Welch and Black, 2010). All cancers, both invasive and non-invasive
DCIS, are considered. Also, for transparency, the calculations are
expressed in terms of numbers of women whereas some authors
have reported rates per 1000 woman years of follow-up.
The Malmo¨ I trial included women aged 45–69 at entry.
Cancer incidence was reported after an average of 15 years of
follow-up (to December 2001) (Zackrisson et al, 2006).
In the active screening period up to 1990, there were 741
cancers diagnosed detected in the screening group and
591 in the control group, an excess of 150. In the period
from 1990 to 2001, a further 579 and 614 new cancers were
diagnosed, respectively, showing a catching up of 35 cancers.
The total numbers of cancers in the screened and control
groups were 1320 and 1205, respectively, showing an overall
excess of 115 cancers diagnosed among screened women.
Zackrisson et al (2006) reported a RR of 1.10 and interpreted
these data as showing an estimated overdiagnosis of 10% (95% CI
1–18%). Reporting such a percentage requires consideration of the
denominator: 10% of what (Fletcher, 2011)? In fact, the figure of
10% represents the estimated excess risk of a diagnosis of breast
cancer among women who had been invited to be screened, and
were followed for 15 years after the trial ended. The figure of
10% thus addresses the first key question stated above – population
impact.
The panel calculated four estimates of percentage overdiagnosis
from the Malmo¨ I trial (Table 2A). The younger women (age
45–54) were offered screening at the end of the study period so the
estimates are shown both for all women (age 45–69 at enrolment)
and only for women aged 55–69. Different definitions of
overdiagnosis lead to estimates ranging from 9 to 29%, although
they are based on the same trial.
To answer the second key question – from the perspective of a
woman being screened, what is the probability that a cancer
diagnosed during the screening period represents overdiagnosis – it
is important to include screen-detected cancers and interval
cancers. Among women being screened, whether in a trial or a
routine screening programme, not all of the diagnosed cancers will
be detected at the routine screening; many cancers will be picked
up between screens, as ‘interval’ cancers and might have presented
symptomatically in the absence of screening. The relative
proportion of interval to screen-detected cancers will increase as
the screening interval increases (Breast Screening Frequency Trial
Group, 2002) – in general more screen-detected cancers implies
fewer interval cancers – so excluding interval cancers will give an
estimate of overdiagnosis subject to screening frequency. Further,
clinical experience suggests that suspicion of cancer may encourage
a woman to accept the invitation to screen. The panel therefore
prefers to use, as a denominator for the risk of overdiagnosis
among women invited for screening, the second key question, the
number of cancers diagnosed in invited women throughout the
period of screening.
Table 2A. Estimates of overdiagnosis from the Malmo¨ I trial, with and without inclusion of women age 45–54.
Description Calculation
Estimated
overdiagnosis
All women (age 45–69)
A. Excess cancers as a proportion of cancers diagnosed over whole follow up period in unscreened womena 115/1205 9.5%
B. Excess cancers as a proportion of cancers diagnosed over whole follow up period in women invited for screening 115/1320 8.7%
C. Excess cancers as a proportion of cancers diagnosed during screening period in women invited for screening 115/741 15.5%
D. Excess cancers as a proportion of cancers detected by screening in women invited for screening (64% of all cancers
detected in screened group)b
115/474 24.3%
Older women (age 55–69)
A. Excess cancers as a proportion of cancers diagnosed over whole follow up period in unscreened womena 82/698 11.7%
B. Excess cancers as a proportion of cancers diagnosed over whole follow up period in women invited for screening 82/780 10.5%
C. Excess cancers as a proportion of cancers diagnosed during screening period in women invited for screening 82/438 18.7%
D. Excess cancers as a proportion of cancers detected by screening in women invited for screening (64% of all cancers
detected in screened group)b
82/282 29.1%
aResult reported by Zackrisson et al (Zackrisson, 2006)
bi.e. excluding all interval cancers.
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4.4 Estimates of overdiagnosis
The literature on overdiagnosis has been reviewed by several
authors since 2005. They used different study inclusion criteria, but
gave most attention to data from RCTs. Moss (2005) calculated
overdiagnosis for eight RCTs as did Gøtzsche (2004) for six of the
same trials. Biesheuvel et al (2007) reviewed the literature with
particular attention given to the RCTs and the two former reviews.
Recently, Puliti et al (2012) reviewed the European literature
covering observational studies. Biesheuvel and Puliti both con-
sidered the issue of bias in each of the studies, specifically in
relation to adjustment for lead time and case-mix.
Moss (2005) and Gøtzsche (2004) produced very different
estimates of overdiagnosis from the same trials. Biesheuvel et al
(2007) converted all their estimates to a common measure of
overdiagnosis (method A described below), but important
discrepancies remained. Biesheuvel et al (2007) reported that in
the studies they considered least biased, overdiagnosis estimates
ranged from  4 to 7.1% for women aged 40–49 years, 1.7 to 54%
for women aged 50–59 years, and 7 to 21% for women aged 60–69
years (Biesheuvel et al, 2007). Similar large variations have been
seen in the estimates of overdiagnosis from observational studies
(Puliti et al, 2012). Some of the variation seen in these age-specific
estimates stems from very small numbers of cases within age
groups within trials.
Given the wide variation in both the methods used and the
estimates obtained, the panel calculated four estimates of
percentage overdiagnosis:
A. Excess cancers as a proportion of cancers diagnosed over whole
follow-up period in unscreened women
B. Excess cancers as a proportion of cancers diagnosed over whole
follow-up period in women invited for screening
C. Excess cancers as a proportion of cancers diagnosed during
screening period in women invited for screening
D. Excess cancers as a proportion of cancers detected at screening
in women invited for screening
RCTs without screening of control group at the end of the trial
The most reliable estimates of overdiagnosis come from RCTs in
which women in the control group were not offered screening at
the end of the trial. Three trials clearly meet this criterion:
Malmo¨ I, for women aged 55–69 years, and the two Canadian trials
that screened women for 5 years and reported follow-up data at 11
years (i.e., about 6 years after the end of screening; Miller et al,
2000, 2002). The estimates of overdiagnosis from these two trials
were quite similar to those from Malmo¨ I.
The situation with the HIP study was less clear from the
available literature, so the panel excluded this study for the
purposes of the estimate of overdiagnosis. In addition, the panel
had difficulty from the published literature extracting the data on
the numbers of cancer cases in the two arms using the same
definition of cases as the other three studies. In particular, the first
report of the HIP study included both DCIS and lobular cancer
in situ (LCIS) in the non-invasive cases (Shapiro, 1977; Shapiro
et al, 1982), but thereafter we could not determine whether LCIS
cases had been included in the subsequent incidence data, nor
whether non-invasive cases had been included in the process of
cross-checking with the New York Cancer registry data and
National Death index (Chu et al, 1988). Estimates of overdiagnosis
from the Malmo¨ I and the two Canadian trials using the four
methods already described are shown in Table 2B. The estimates
from the three RCTs are quite similar.
Opportunistic screening in the control group would lead to an
underestimate of overdiagnosis. In the Malmo¨ and Canadian trials,
about 25% (26% and 17%, respectively, in the two Canadian trials)
of the women in the control group reported having received a
mammogram both during the active trial period and follow-up
period. No allowance has been made in the above calculations for
that effect.
All four methods use the same numerator, derived from the
difference in newly diagnosed cases of breast cancer in the group
invited for screening and the control group. Methods A and B
differ in whether they compare the excess against the number of
cancers diagnosed in the control group or the screening group.
Many published estimates use the former (method A).
None of the methods are wrong – they just address different
questions. The panel’s preferred measures are method B to address
the population perspective and method C for the perspective of an
individual woman. Figure 3C shows the results from random effects
meta-analyses for these two estimates of overdiagnosis.
As many have noted, these three RCTs offer the most reliable
evidence for an estimate of overdiagnosis. The combined data
suggest a risk of overdiagnosis of about 11% with a population
perspective and 19% from the individual woman’s perspective.
The panel considers the data consistent with overdiagnosis of
about 5–15% from the population perspective and 15–25% from
the individual woman’s perspective. These estimates are subject to
the same sources of uncertainty as noted for the estimates of
mortality from the RCTs. In addition, the estimates are not tailored
to the UK screening scheme or a 20-year screening period.
In total, these three trials included only 1200 cancers diagnosed
during the screening period of which an estimated 243 were
overdiagnosed. Given these small numbers, it is important to
consider other estimates from other RCTs and the higher quality
observational studies. However, those studies clearly provide less
reliable estimates.
RCTs with screening of control group at the end of the trial
In several RCTs, all the women in the control group were offered
screening at the end of the active phase of the trial. Estimates of
overdiagnosis from these trials are problematic. Exclusion of
cancers detected at the end-of-trial screening of the control group
would overestimate overdiagnosis, as the control women have not
been followed long enough. Such an effect is clearly seen in the
RCTs without end-of-trial screening. On the other hand, inclusion
of cases detected at the end-of-trial screen of women in the control
group means that screening is not being compared with no
screening. Also, some of the cancers detected by that screen would
themselves be overdiagnosed. Thus, including these cancers would
lead to an underestimate of overdiagnosis.
Although for several trials both calculations just described are
possible, the estimates obtained generally vary widely. For example,
for the Stockholm trial using method B, the estimate of
overdiagnosis varies from  2.6% from all diagnosed cancers to
þ 39% if cancers detected at the end-of-trial screen of the control
group are excluded. Although it is reasonable to believe that these
two estimates bracket the desired answer (had there been no extra
screen and with extended follow-up), the panel believes it is
impossible to get useful and reliable estimates of overdiagnosis
Table 2B. Randomised trials without screening invitation to the control
group (Miller et al, 2000; Miller et al, 2002; Zackrisson et al, 2006)
A B C D
Malmo¨ I
55–69
11.7% (82/698) 10.5% (82/780) 18.7% (82/438) 29.1% (82/282)
Canada 1 14.1% (82/581) 12.4% (82/663) 22.7% (82/361) 29.4% (82/279)
Canada 2 10.7% (67/626) 9.7% (67/693) 16.0% (67/420) 19.8% (67/338)
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from these trials. An alternative approach is to estimate the effect
of lead time and adjust for it. That approach makes very strong,
unverifiable assumptions, and the panel is not persuaded that such
an adjustment can be made reliably.
Observational studies
Overdiagnosis can be estimated from some non-RCTs, but as always
with observational studies there are serious concerns about
comparability. Numerous observational studies have adopted a
variety of study designs to compare screened and unscreened women
or, more often, women who were or were not invited to screening.
There is a considerable body of literature examining the effects
of screening in populations and trying to assess the degree of
overdiagnosis. Even in the absence of screening, breast cancer
incidence rates are not stable over time in populations, and the
wide variation in quoted overdiagnosis rates reflects this variation
as well as different lengths of follow-up, different statistical
assumptions, and different ways of accounting for lead time.
When screening is introduced there will be a short-term rise in
the incidence of newly diagnosed cancers. If that rise is solely due
to advancing the time when some cancers are diagnosed the
increase should fall back to pre-screening levels after some years. A
failure to do so may be interpreted as evidence of a degree of
overdiagnosis (Esserman et al, 2009). Time trends can also be
examined for women of different age groups: before, during, and
after the screening programme age range. Such data are shown in
Figure 1A in section 2 for breast cancer incidence in the United
Kingdom. The increase in incidence associated with the introduc-
tion of population screening is clearly seen, first for women aged
50–64 and later for women aged 65–69.
Some studies have compared post-screening incidence with a
projection of previous incidence trends in the screened population.
Those studies have resulted in very different estimates of
overdiagnosis. The panel asked Cancer Research UK to review a
set of plausible assumptions made in the literature and to produce
estimates based on these assumptions (Jørgensen and Gøtzsche,
2009a; Duffy et al, 2010). The panel found that by changing each of
the assumptions, one could get a vast range of estimates of
overdiagnosis (Appendix 6). The results of the modelling produced
a range of estimates for the impact of the current NHS breast
screening programme in England from 0 to 46550 women (aged
X45) per year in England. Ten per cent of the results wereo1150
and ten per cent44115. As there appears to be no a priori reason
to favour one set of assumptions over another, the panel do not
think that approaches based on extrapolation offer a robust
method to estimate overdiagnosis.
Several groups have compared breast cancer incidence trends
over time in screened and unscreened countries or regions over the
same time period (Jørgensen and Gøtzsche, 2009). The difficulty
with these studies is distinguishing true overdiagnosis from the
excess incidence of breast cancer that results from screening,
bringing forward the time of diagnosis. Given that overdiagnosis is
defined as a cancer that would not have come to attention in the
woman’s life span, long follow-up after cessation of screening is
essential. The difficulties can be illustrated by studies of comparisons
of incidence rates in regions within a single country that did or did
not introduce population screening. A study from Denmark is
illustrative, as only 20% of the Danish population was offered
organised mammography screening over a long time-period
(Jørgensen et al, 2009). Screening was introduced in Copenhagen
in 1991 and in Funen in 1993 for women aged 50–69. The authors
noted that the population in those areas has distributions of age and
socioeconomic status comparable with the rest of Denmark.
Table 2C shows the numbers of breast cancers diagnosed per
100 000 women in screened and non-screened areas of Denmark for
20 years before and 13 years after the introduction of screening in
1991. Incidence rates of breast cancer were higher in the screened
areas than in the non-screened areas before screening began,
suggesting some non-comparability of the areas. During the 13 years
of screening, the incidence in women aged 50–69 rose both in the
screened areas and the non-screened areas, but more in the screened
areas. Incidence also rose in women aged 70–79. One way to
estimate overdiagnosis is to compare the ratio of new cancers in
screened and unscreened groups in the two periods. In the pre-
screening period, the ratio was 1.08 (214/198) and for the screening
period it was 1.35 (386/286). The authors say that these data indicate
35% overdiagnosis, but if we adjust for the pre-screening difference
the excess is 25% (1.35/1.08¼ 1.25). These simple calculations
ignore the underlying rise in cancer incidence throughout the
period. The authors used regression modelling to take account of
incidence trends and age differences, giving an estimate of 33%. As
noted earlier, such analyses make additional assumptions that are
not verifiable. Studies such as this do not indicate the likely effect of
long-term follow-up in reducing the excess in the incidence rate in
the screened compared with the unscreened populations.
There have been many other observational studies, but most have
the type of problem illustrated here in distinguishing overdiagnosis
from the expected increase in breast cancer incidence due to
screening and require many assumptions to derive estimates of
overdiagnosis. A recent review of 13 observational studies showed
overdiagnosis to vary in the range of 0–54%. Adjustment for lead
time and breast cancer risk yielded overdiagnosis estimates in the
range of 1–10% (Puliti et al, 2012).
The panel’s judgement is that the best estimates will come from
long-term follow-up of RCTs, as reviewed above.
Statistical and other uncertainties
As noted in section 3, it is conventional that results from statistical
analyses, including meta-analyses, are presented with a measure of
statistical uncertainty such as 95% confidence limits. Although
these are helpful in giving an impression of the possible influence
of the play of chance (given the sample sizes that are available in
the studies considered), they fail to represent the uncertainties due
to possible biases (internal validity of the studies) or to general-
isation from the studies to a new context (external validity). So the
CIs given for the estimated percentage overdiagnosis are an
understatement of the uncertainty about the risk of overdiagnosis
associated with the UK screening programmes. Estimates of
overdiagnosis have additional uncertainties relating to which
estimate to use, and the data are not available for all studies to
calculate overdiagnosis in the suggested ways.
Conclusion
The panel believes that overdiagnosis occurs, and that women need to
be aware that screening carries a risk of detecting cancers, invasive and
Table 2C. Breast cancer incidence rates per 100 000 women in screened
and non-screened areas, before and after screening started, and during
the last three years of observation (Jørgensen et al, 2009)
Screened areas Non-screened areas
1971–1990 1991–2003 1971–1990 1991–2003
No screening Screening
Age group
35–49 120 128 111 120
50–69 214 386 198 286
70–79 273 340 264 309
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in situ, which would not have troubled them in their lifetime.
Tumours that represent overdiagnosis cannot be identified clinically
and so will have to be managed according to current clinical protocols.
The panel considers that the data from three of the RCTs
without end-of-trial screening of controls provide the most reliable
estimates of the extent of overdiagnosis, but notes that there is a
rather limited amount of data and numerical estimates are subject
to several uncertainties in common with estimates of mortality
benefit.
As noted for the estimated benefit for mortality (see section 3.2),
the overdiagnosis rates estimated from old RCTs may not reflect
those in current screening programmes. There is, however, no clear
evidence to suggest that the current rate of overdiagnosis would be
lower or higher than in the original trials. The panel thinks that the
best estimate of overdiagnosis for a population invited to be
screened is of the order of 11%, defined as the percentage excess
incidence in the screening population above the long-term
expected incidence in the absence of screening.
An alternative definition addresses the answer to the question ‘if
I am invited to enter into the screening programme and am given a
cancer diagnosis during the screening period, what is the likelihood
of overdiagnosis’? The panel views the evidence as suggesting that
this probability is of the order of 19%.
4.5 Consequences of overdiagnosis
As previously stated, detection of overdiagnosed cancers turns
women into patients, leads to surgery and other treatments that are
not therapeutically beneficial for these women and can cause harm,
and adversely affects their quality of life. As cancers that would not
go on to cause cancer death cannot be individually identified, they
are treated according to the current treatment protocols. Figure 3D
summarises the management of UK screen-detected cancers, both
invasive and non-invasive, in 2010/2011 (NHS Breast Screening
Programme & Association of Breast Surgery-West Midlands
Cancer Intelligence Unit, 2012).
One cannot, however, assume that the overdiagnosed cancers
would be managed in the same proportional way as the generality
of screen-detected cancers. That the patient dies before the cancer
would have presented clinically, implies that such tumours:
 would tend to be more slowly growing, as a more rapidly
growing tumour would be more likely to present clinically within
a shorter time-frame;
 would be relatively small, as larger tumours would be more likely
to present symptomatically.
Thus, overdiagnosed cancers would tend to be more likely to be:
 DCIS (and the relative excess of DCIS in screen-detected cancers
would support this), and possibly more likely to be low/
intermediate rather than high grade.
 Grade 1 or grade 2 invasive rather than grade 3.
Thus, compared with the diagram, patients with cancers that are
overdiagnosed would be:
 relatively more likely to have been treated on the DCIS side than
the invasive; and as more likely to be low/intermediate grade, less
likely to have had radiotherapy;
 if invasive, more likely to be managed by WLE and radiotherapy
than mastectomy as likely to be small
 if an invasive cancer, less likely to have had chemotherapy, as
patients having chemotherapy are more likely to have had
grade 3 and/or node-positive cancers (NHS Breast Screening
Programme & Association of Breast Surgery-West Midlands
Cancer Intelligence Unit, 2012);
 if an invasive cancer, more likely to have had endocrine therapy,
as oestrogen positivity is associated with older age and lower
grade invasive cancers.
Evidence in support of this tendency for overdiagnosed cancers
to be of potentially better prognosis, and thus given less aggressive
therapy can be seen, for example, in the reports of the nature of
cancers found in the two arms of randomised screening trials.
Table 2D shows such data for the Malmo¨ I trial.
4.6 Ductal carcinoma in situ (DCIS)
There is evidence that breast screening has led to an increase in the
identification of DCIS (IARC, 2002). It has been suggested that
DCIS is a relatively benign condition that would not cause harm,
and therefore diagnosis of DCIS contributes significantly to the
magnitude of overdiagnosis.
Definition
DCIS is a malignant process that arises from the epithelial tissues
of the breast, and consists of neoplastic cells, which do not,
however, infiltrate beyond the limiting basement membrane, and
thus remain within the ducts where they arose. Classification is
based on the morphological features: architectural growth
pattern and the cytological characteristics of the malignant cells.
It is usually grouped by grade into high, intermediate, or low grade
(IARC, 2002). Along with LCIS, it is classified as non-invasive
breast cancer, and although the cells have the appearance of
malignancy, they do not show invasiveness, so carcinoma in situ is
not in itself a life threatening condition. The concern is that at least
some have the capacity to progress to invasive malignancy.
DCIS is most commonly detected mammographically as
microcalcification. Less commonly, DCIS will present with a
symptomatic lump.
Incidence
Table 2E adapted from ‘The non-invasive breast cancer report’
(National Cancer Intelligence Network, 2011), shows the frequency of
non-invasive breast cancer for different age groups and presentations
in England for the two years 2006 and 2007.
The majority (about 90%) of non-invasive cancers diagnosed are
DCIS. It is apparent that the majority are screen-detected but,
nevertheless, 38% were diagnosed symptomatically. Some of the
symptomatic tumours may have been detected incidentally when
patients presented with a different problem (e.g. microcalcifications
found in the contralateral breast when the woman has presented
with a benign problem in the one breast). Thus, the detection and
management of non-invasive disease is not exclusively a problem of
the screening programme. Nevertheless, within the screening age
group (age 50–70), the majority (79%) of the DCIS is screen-
detected. For 2009–2010, of all screen-detected cancers, about one in
five were non-invasive, being a little higher (24%) for the prevalent
round and lower (19%) for the incident rounds (The NHS
Information Centre, Public Health Indicators Team, 2011). Thus,
a mammographic screening programme will detect DCIS. In some
cases, (about one in five) (Evans, 2012) investigation of what is
radiologically DCIS will lead to the detection of an invasive
carcinoma – the larger the area of DCIS, the more likely that there
will be a frankly invasive component.
Natural history of DCIS
Before introduction of the screening programme, DCIS was a
relatively uncommon tumour. Since it is frequently a marker of
associated invasive cancer, it has been investigated and usually
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excised, and hence it is not possible to know what would have
happened if it had been left undisturbed and untreated. Given that
the screening programme is diagnosing much more DCIS than
presents symptomatically, the relevant questions are:
How common is DCIS?
As above, it represents about 1 in 5 of screen-detected cancers, but
only 1 in 20 of all symptomatic cases (National Cancer Intelligence
Network, 2011). In reports of small series (IARC, 2002) of women
without known breast cancer who underwent postmortems
(hospital-based or forensic), invasive cancer was found in about
1% and DCIS in 9%, but there was wide variation in the series,
presumably reflecting differences in the women selected and
methodologies for examining the breast.
How often does it progress to invasive cancer?
The data from trials of therapy (radiotherapy and/or tamoxifen) after
WLE of DCIS shows that both interventions reduce the risk of local
relapse (similar to the findings for invasive cancer after WLE).
Relevant to the UK screening programme is the UK, Australia, New
Zealand (UK/ANZ) trial (Cuzick et al, 2011), in which after WLE of
screen-detected DCIS, without any further treatment, relapse in the
breast occurred in about 19% of cases, in half of which the relapse
was invasive. Progression appears to occur slowly – for example, one
series of screen-detected DCIS (Wallis et al, 2012) showed the
median time to invasive progression for high-grade DCIS was 76
months, and for low/intermediate grade 131 months.
Is there any way of identifying those cases of DCIS that will or
will not progress/relapse as invasive cancer?
DCIS is classified histologically on the basis of excised speci-
mens, and there is currently no certain means of identifying
lesions that would not progress. The risk of invasive relapse is
higher with high- or intermediate-grade DCIS. Low-grade DCIS
seems to pursue a more indolent course, and when invasive
relapse occurs it is likely to be a grade-1 tumour. There is
ongoing work (Pinder et al, 2010; Reeves et al, 2012) looking at
histological and molecular markers to identify those most likely
to progress, especially to invasive disease.
Does DCIS affect survival?
The follow-up of patients with DCIS usually shows excellent
survival. For example, in the UK/ANZ trial of 1701 women
with a median follow-up of 12.7 years, only 179 (11%) had
died, of which 39 (2% of all cases) died of breast cancer. Long-term
follow-up (NHS Breast Screening Programme & Association of
Breast Surgery-West Midlands Cancer Intelligence Unit, 2012) of
1603 cases of screen-detected non-invasive breast cancer (nearly all
DCIS) showed a 20-year relative survival of 97.2% (95% CI 93.6–
100.6), with 7.2% of the 493 deaths being due to breast cancer.
However, these series are of patients who have had the DCIS treated:
what is unclear is what the risk of dying of breast cancer would have
been had it been left untreated.
Conclusions
The main question is whether DCIS is a marker of malignancy
requiring active treatment or a benign condition of no clinical
significance. On the one hand, DCIS (particularly high grade)
can certainly serve as a marker for invasive cancer – either
because it is associated with the presence of invasive disease
at the time of detection, or because its presence indicates
an increased risk of invasive disease developing subsequently –
in about 10% of cases at 10 years after WLE only. On the other
hand, autopsy series and screening programmes both demon-
strate that DCIS can be found in the breast of middle-aged
women at a greater frequency than presents symptomatically.
Part of the explanation is time. Breast cancer has a long
natural history and in patients with invasive cancer, the
evolution of metastatic spread and ultimate death may take
place over decades. If one also considers the progression of
DCIS to invasive cancer as part of this process, the evolution is
even longer. In other words, the relevant question is not
whether DCIS progresses to invasive cancer (it can), but
whether it might have progressed to an invasive cancer that
causes symptoms within the lifetime of the women concerned.
This will depend mainly on the age of the woman, her life
expectancy at the point of diagnosis, and perhaps other factors
that could affect progression (hormonal exposure, obesity, etc.).
Current series do not show a significant impact of DCIS on
survival, after treatment, even at 20 years, but increasing
survival may mean that for women in their 50s and even 60s,
the diagnosis of DCIS may impact on their long-term survival.
Long-term data are needed.
Thus, in diagnosing DCIS via a screening programme, there is a
balance to be struck between the potential benefits for some
women of identifying and treating a pre-invasive cancer, and the
risks for others of treating something that would never have
affected the woman in her lifetime. It is not simply the case that
DCIS represents overdiagnosis, although it undoubtedly is a
contribution to the cases of overdiagnosis.
Table 2D. Characteristics of cancers diagnosed in Malmo¨ I trial
(Andersson et al, 1988)
After 5 complete rounds of
screening
Mammography
group
Control
group
Non-invasive 93 (16%) 53 (11%)
Stage 1 296 (51%) 162 (37%)
Stage 2 142 (25%) 172 (39%)
Stage 3 26 (4%) 27 (6%)
Stage 4 22 (4%) 32 (7%)
Given chemotherapy 26 (5%) 41 (9%)
Table 2E. Frequency of non-invasive breast cancer, England 2006 & 2007
(National Cancer Intelligence Network, 2011)
Non-invasive breast cancer Total invasive.
Age
Symptomatic
(%)
Screen
detected
(%)
Total
non-
invasive No.
% non-
invasivea
o50 1060 (94) 70 (6) 1130 15589 7
50–70 1241 (21) 4654 (79) 5895 43379 12
470 738 (76) 227 (24) 965 23930 4
All ages 3039 (38) 4951 (62) 7990 82899 9
a% is non invasive as a % of invasive and non-invasive tumours combined.
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5. OTHER CONSIDERATIONS
5.1 Introduction
Beside the benefit of breast screening for mortality and its harm in
terms of overdiagnosis, the panel considered other relevant issues.
These include additional harms through invitation, screening,
diagnosis, and treatment, as well as women’s perceptions and cost
effectiveness. Although the panel has not made a systematic
appraisal of evidence in all these areas, being outside its terms of
reference (Appendix 1), it has drawn together comments on each
of these issues as they should not be neglected when considering
the overall impacts of breast screening.
5.2 Harms associated with breast screening
Mammography
Radiation exposure: Mammography uses X-rays and thus
exposes women to very low doses of ionising radiation that could
cause breast cancers. The actual dose of radiation depends on
several factors including the number of views of each breast and
whether film or digital mammography is used.
The Health Protection Agency (Health Protection Agency 2001)
has suggested that the lifetime additional cancer risk for each
mammography examination is between 1 in 1 00 000 and 1 in 10 000.
Although these doses are lower than those for which cancer is
directly induced (Preston et al, 2002), screening a large population on
a regular basis may cause harm. The NHS Breast Screening
Programme (2011) in 2006 stated that for every 14 000 women in
the age range 50–70 years screened by the NHSBSP three times over
a 10-year period, the associated exposure to X-rays will induce about
one potentially fatal breast cancer. (NHS Breast Screening
Programme & Association of Breast Surgery-West Midlands
Cancer Intelligence Unit, 2012). A more recent estimate is that
screening women every 3 years from age 47–73 would cause 3–6
cancers per 10 000 women screened (Berrington de Gonzalez, 2011).
This risk is incorporated in estimates of the benefit of screening (see
section 3). Digital mammography, which uses a lower radiation dose,
is increasingly being used in the English screening programme.
Therefore, it is likely that the risk of exposure will be reduced.
Pain: During the process of mammography, the breast is
compressed and flattened in order to create a uniform density,
which improves the image and reduces the radiation dose. A
substantial proportion of women find this painful and some studies
(Nelson et al, 2009; Gøtzsche and Nielsen, 2011) have shown that
the pain and discomfort of mammography deters them from
attending for further screening (Gøtzsche and Nielsen, 2011).
The assessment process
Figure 4 summarises the process and numbers for women recalled
after routine screening mammograms Figure 4.
Many women take part in the screening programme; it is often
argued that for many the benefit will be reassurance (Welch et al,
2011). With that reassurance, however, must come the knowledge that
all screening tests have errors of false positives and false negatives. The
mammogram may sometimes appear to show an abnormality that
requires further investigation to determine whether or not it is a
cancer-requiring treatment or fail to detect a cancer that is present.
False-positive mammogram
In Figure 4, 2522 women (i.e., 3105 recalled minus the 583 diag-
nosed with cancer¼ 2522: 3.36% of all the women screened) were
recalled and found not to have cancer. This is called a false-positive
result. Of the women recalled and found not to have cancer, the
majority (1744/2522¼ 69%) had only further imaging (mammo-
graphy, ultrasound) but a minority (778/2522¼ 31%) had a biopsy,
which was core biopsy under local anaesthetic in all except 2.3%
(57/2522) who had a formal biopsy under general anaesthetic. The
latter group represents only 0.076% (57/75 057) of all women
screened.
Numerous studies have assessed the psychological impact of a
false-positive result on women (Brett et al, 1998; Brett
and Austoker, 2001). The studies’ results are conflicting but a
recent systematic review of the literature (Bond et al, 2012)
concluded that, in the population at general risk of breast cancer, a
false-positive result can cause breast cancer-specific psychological
distress, which may endure for up to 3 years. The degree of distress
is associated with the level of invasiveness of subsequent
assessment. Some studies found that the distress caused by a
false-positive result deterred some women from re-attending for
breast screening, which would reduce any benefit they would
otherwise have got from being offered screening in the first place.
The level of distress can be mitigated by providing women with
clearly worded information about the recall and appropriate
support from clinical staff in before and during assessment (Bond
et al, 2012).
False-negative results
No screening test is completely accurate and sometimes mammo-
graphy will not detect a cancer. This may because the cancer is not
mammographically visible or develops between screening rounds
and women are warned of this possibility in the screening
literature. When women present with an interval cancer, the
previous mammograms are reviewed blind to assess whether a
suspicious abnormality was visible on the previous screening
Women invited
100 000
Women screened
75 057
Women recalled
3105 (4.1%)
Breast cancers detected
583 (18.8%)
DCIS
115 (19.7%)
Invasive cancers
468 (80.3%)
Benign open biopsy
57 (1.8%)
Benign core biopsy
721 (23.2%)
Attend from invite
73 426 (73.4%)
Attend from self / GP referral
1361
Figure 4. The assessment process. Overall cancer detection rate is
583/75 057¼ 7.8 cancers per 1000 women screened. Of the 3105
women recalled, 583 (18.7%) will be diagnosed with invasive or in situ
cancer. Data extracted for women aged 50–70 for year 2009/10
(NHS Breast Screening Programme, 2011; NHS Breast Screening
Programme & Association of Breast Surgery-West Midlands Cancer
Intelligence Unit, 2012).
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mammogram. If so, such cases are classified as a true false-negative
mammogram, that is, the suspicious abnormality was missed at the
first screen. For women attending at three yearly intervals, the
false-negative rate is 0.2/1000 women screened (Lawrence, 2012;
c.f. the cancer detection rate by screening of 7.8 cancers/1000
women screened).
Diagnostic testing
Core biopsy carries a risk of local haemorrhage and, rarely,
reaction to local anaesthetics. Open surgical biopsy involves a
general anaesthetic but it is regarded as a low-risk procedure.
Psychological consequences of a positive diagnosis
The psychological consequences of a breast cancer diagnosis and
subsequent treatment have been well documented. In terms of
harms of screening, these consequences are particularly relevant to
those women who have been overdiagnosed. Although these
women will not know that the cancer would not have caused them
any harm they will have suffered unnecessary psychological trauma
associated with a cancer diagnosis
Two studies (Yousaf et al, 2005; Schairer et al, 2006) have shown
a small but significant increased risk of suicide in patients
diagnosed with breast cancer. The risk increases with advancing
stage of the disease and therefore may be less relevant for those
who are overdiagnosed. However, two further studies (Jamison
et al, 1978; de Leo et al, 1991) have found suicidal ideation to be
present in some patients post-mastectomy. Although these risks
are small they should not be overlooked when assessing the
benefits and harms of breast screening.
Potential morbidity and mortality from treatment
Breast surgery: As with any surgical procedure, there are hazards
from the anaesthetic and the surgical procedure itself. Although the
surgery can be extensive (especially if it involves reconstructive
surgery as well), the surgery is elective, patients are assessed pre-
operatively, serious complications are rare. The most extensive
surgery is mastectomy and reconstruction for which the mortality
is estimated to be o0.3% (The NHS Information Centre, Public
Health Indicators Team, 2011). In contrast, following mastectomy,
10% of patients will have some sort of complication (e.g. infection,
fluid accumulation) (The NHS Information Centre, Public Health
Indicators Team, 2011).
Radiotherapy: Acutely, radiotherapy can cause skin reactions and
uncommonly radiation pneumonitis. Both of these are short-lived
and usually not severe.
Radiotherapy can cause other long-term harms (Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG), 2005).
There is, at 15 years, a small excess risk of non-breast cancer
mortality (15.9 vs 14.6%, an absolute difference of 1.3%). This is
mainly due to heart disease (so seen more in left- than right-sided
cases because more of the heart is irradiated), lung, and
oesophageal cancers. These estimates are derived from trials of
radiotherapy performed mostly during or before the 1970s; since
then radiotherapy techniques have changed especially with the
introduction of CT planning, so reducing the volume of heart and
lung irradiated, which should reduce, but not eliminate, such
complications. Data from the Surveillance Epidemiology and End
Results (SEER) database (Giordano et al, 2005) shows that the risk
of death from ischaemic heart disease due to radiotherapy has
diminished from 1973 to 1989 (risk from right-sided tumours
unchanged, left sided decreased).
The last published Oxford overview (Clarke et al, 2005) showed
that there is a reduction in mortality from the reduction in
local recurrence of invasive cancer by radiotherapy. Essentially, for
every four recurrences prevented at 5 years, there will be one
death prevented at 15 years. For illustration, the local recurrence
rate in the radiotherapy START trial (in which many patients had
screen-detected cancers) was 3.5% at 5 years, which, given
radiotherapy reduces local recurrence by about two-thirds, would
correspond to a 5-year local recurrence rate of about 10.5% without
radiotherapy. This gain of 7% in local control should correspond to
a reduction in mortality of just under 2%.
Adjuvant hormone therapy: The most extensive experience is
with tamoxifen. Trials of adjuvant tamoxifen for 5 years have
shown that for patients with hormone receptor-positive breast
cancer, breast cancer mortality is reduced by about 33% (Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG) 2005),
translating into an absolute reduction in mortality at 10 years of
5.3% and 12.2% for node-negative and node-positive patients,
respectively. Tamoxifen does have some long-term hazards in that
it carries an increased risk of uterine cancer and thromboembolic
disease. Their effect on mortality is of the order of 0.2% per decade
and is outweighed by the modest but positive effect of tamoxifen
on ischaemic heart disease (possibly because it lowers cholesterol)
(Dewar et al, 1992). Aromatase inhibitors are increasingly used
instead of tamoxifen, but their overall effect on mortality is very
similar to that of tamoxifen.
Cytotoxic chemotherapy: Adjuvant cytotoxic chemotherapy
reduces both overall and breast cancer-specific mortality. Use of
an anthracycline- or taxane-containing regime yields a RR
reduction of about one third in breast cancer mortality (Peto
et al, 2012). The absolute benefit depends on the risk profile but
will often be of the order of 6–7% at 10 years. There are acute
toxicities associated with giving chemotherapy — such as alopecia,
nausea and vomiting, which are all unpleasant but non-fatal. Acute
neutropenic sepsis can be fatal but this is a rare event in the
adjuvant setting. There is an increased risk of thromboembolism.
Mortality rates during adjuvant chemotherapy have been reported
at around 0.3% (Cameron et al, 2003). The main long-term risks
are (Azim et al, 2011):
 Cardiac: Anthracyclines can cause a cardiomyopathy, the
incidence being dose related and increasing with age. Trials
suggest an absolute excess mortality of up to 1%, but this may be
an underestimate as the incidence of cardiac failure may be
higher and can occur many years after treatment.
 Second cancers: The main risk with chemotherapy, particularly
anthracycline-based, appears to be acute myeloid leukaemia and
myelodysplastic syndrome. At standard doses, the risk is
probably of the order of 0.5% but may be higher if the doses
(especially of alkylating agents and anthracyclines) are increased.
 Neurotoxicity and premature menopause: Both are very real
causes of morbidity but not of mortality.
Conclusion
We know that within the NHS screening programmes, of patients
found to have invasive or non-invasive cancer, 99% have
surgery (of whom 5.7% have mastectomy and immediate
reconstruction), 72% have radiotherapy, 72% have adjuvant
hormone therapy, and 27% adjuvant chemotherapy (NHS Breast
Screening Programme & Association of Breast Surgery-West
Midlands Cancer Intelligence Unit, 2012). From the above,
assuming a worst case scenario, it would be reasonable to assume
no adverse mortality effect for hormone therapy, no net effect of
radiotherapy on mortality, a maximum of 0.2 per 1000 dying
because of surgery (0.3% of those having reconstruction) and 1.3
per 1000 dying because of chemotherapy (0.5% of the 27% who
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have chemotherapy), giving an adverse mortality rate of 0.15%. For
patients who have an ‘overdiagnosed’ cancer, the risk is likely to be
lower as it is unlikely that they would have received chemotherapy
(see section 4).
 The panel concludes that the excess mortality from the
investigation and treatment of invasive breast cancer is small
and outweighed by the benefits of the treatment.
For DCIS, the benefits of radiotherapy or hormone therapy are in
terms of recurrence rather than a reduction in mortality, but the
absolute risks of such treatment in terms of mortality are likely to be
very small. For patients with screen-detected breast cancer, there is no
evidence that these risks are any greater than in the symptomatic
population, but for women diagnosed with a breast cancer, that if it
were certain would never be symptomatic, there is nevertheless a real,
but very small, mortality risk from being screened.
5.3 Women’s perceptions of screening
The development of new information to accompany cancer
screening invitations was not in scope for this review and is being
dealt with separately. Women’s perspectives on overdiagnosis and
whether they see it as a key issue in their screening decisions had
not previously been investigated, so Cancer Research UK
commissioned some qualitative research to investigate this. The
findings, from one focus group attended by panel members, are
presented briefly here for information (Appendix 5), but academic
papers, focusing on a larger sample of qualitative research, will
follow publication of this report.
These women understood the concept of screening and most
had attended. Although they understood breast cancer, and many
knew people who had had it, they had little concept of DCIS and
overdiagnosis. Their opinions are not mainly informed by the
screening leaflet, and it would appear many do not read it in detail.
Thus, informing women about screening will involve much more
than simply re-writing the leaflet.
5.4 Cost-effectiveness of breast screening
It was not in the panel’s remit to review the data relating to the
costs or the cost-effectiveness of breast cancer screening. The
Department of Health in England has provided funds of about
d100 million per year to deliver the current screening programme
(NHS Breast Screening Programme, 2012).
If one were to take the well-founded cost-effectiveness approach
such as that employed by the National Institute for Health and
Clinical Excellence (NICE) when reviewing a health technology, it
would be important to establish the costs not only of the
intervention, but of all subsequent interventions, both in those
invited to be screened and those not offered screening. No such
data are available for any of the randomised trials, and thus this
panel is not in a position to consider the full costs of a breast
screening programme, including the financial costs to the NHS of
any overdiagnosed cancers.
Thus, although it has been estimated that the UK NHSBSP
comes within the NICE cost/quality-adjusted life year threshold of
d20 000–30 000 (Advisory Committee on Breast Cancer Screening,
2006), the panel is not able to comment on this, as it has not been
able to scrutinise the costs of treatment with and without
screening, including the costs of treating the cancers that are
overdiagnosed.
We can, however, make general comparisons with other
interventions and see that, in terms of lives saved per year, breast
cancer screening is of a similar order of magnitude as cervical
screening, bowel cancer screening using faecal occult blood testing
and, the use of statins (Table 3).
6. CONCLUSIONS AND RECOMMENDATIONS
6.1 Recommendations for further research
The panel’s review of the randomised trials of breast screening leads to
the following recommendations about future research priorities:
 An individual participant data meta-analysis of the breast screening
trials is in progress. This should help resolve some (but not all) of the
concerns that have been raised about individual trials and their
combined interpretation. The panel supports this enterprise, and is
disappointed that it had already not been done a long time ago.
 The impact of breast screening outside the ages 50–69 years is
very uncertain. The panel supports the principle of the ongoing
trial in the United Kingdom for randomising women under age
50 and above age 70 to be invited for breast screening.
The panel’s review of overdiagnosis leads to their support for
further research into DCIS, in particular:
 A proposed study to examine the need for treatment of low-
grade DCIS
 Continued support for the Sloane project, which has an
extensive database of screen-detected cases of DCIS,
and the long-term follow-up of these cases may well improve
our understanding of this condition (The Sloane Project
2010, 2011).
 Current mammographic screening techniques now detect
many more cases of DCIS than in the trials. The appropriate
treatment of these is uncertain, because there is limited
information on their natural history (section 4.6). The panel
supports studies to elucidate the appropriate treatment of
screen-detected DCIS.
 Work on improved screening and pathological techniques that
can predict prognosis more effectively.
The panel also supports:
 A re-evaluation of the cost-effectiveness of the NHS breast
cancer screening programme that takes into account the
conclusion of this report.
Table 3. Comparison of public health interventions
Intervention
Number lives saved
per year
Breast screening for women aged
50–69
1300
Cervical screening (with liquid
based cytology)
4500 (Peto et al, 2004)
Bowel screening with biennial FOBT 1800–2400 (Parkin et al, 2008)
Use of statins 9700 (Department of Health, 2006)
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6.2 Conclusions
Breast screening extends lives. The panel’s review of the evidence
on benefit – the older RCTs, and those more recent observational
studies judged to be relevant – point to a 20% reduction in
mortality in women invited to screening. A great deal of
uncertainty surrounds this estimate but it represents the panel’s
overview of the evidence. This corresponds to one breast cancer
death averted for every 235 women invited to screening, and one
death averted for every 180 women who attend screening.
The breast screening programmes in the United Kingdom,
inviting women aged 50–70 every 3 years, probably prevent about
1300 breast cancer deaths a year, equivalent to about 22 000 years
of life being saved; a most welcome benefit to women and to the
public health.
But there is a cost to women’s well-being. In addition to
extending lives by early detection and treatment, mammographic
screening detects cancers, proven to be cancers by pathological
testing, that would not have come to clinical attention in the
woman’s life were it not for screening - called overdiagnosis. The
consequence of overdiagnosis is that women have their cancer
treated by surgery, and in many cases radiotherapy and medication,
but neither the woman nor her doctor can know whether this
particular cancer would be one that would have become apparent
without screening and could possibly lead to death, or one that
would have remained undetected for the rest of the woman’s life.
The answer the panel sought was to the question of the level of
overdiagnosis in women screened for 20 years and followed to the
end of their lives. Estimates abound of overdiagnosis, from near to
zero to 50%, but there are no reliable data to answer this question.
There has not even been agreement on how to measure it. On the
basis of follow-up of three RCTs, the panel estimated that in
women invited to screening, about 11% of the cancers diagnosed in
their lifetime constitute overdiagnosis, and about 19% of the
cancers diagnosed during the period that women are actually in the
screening programme. However, the panel emphasises, these
figures are the best estimates from a paucity of reliable data. Any
excess mortality stemming from investigation and treatment of
breast cancer is considered by the panel to be minimal and
considerably outweighed by the benefits of treatment.
Putting together benefit and overdiagnosis from the above
figures, the panel estimates that for 10 000 UK women invited to
screening from age 50 for 20 years, about 681 cancers will be found
of which 129 will represent overdiagnosis, and 43 deaths from
breast cancer will be prevented. In round terms, therefore, for each
breast cancer death prevented about three overdiagnosed cases
will be identified and treated. Of the B307 000 women aged
50–52 who are invited to screening each year, just over 1% would
have an overdiagnosed cancer during the next 20 years. Given the
uncertainties around the estimates, the figures quoted give a
spurious impression of accuracy.
6.3 Policy recommendations
The panel concludes that the UK breast screening programmes
confer significant benefit and should continue. The greater the
proportion of women who accept the invitation to be screened,
the greater is the benefit to population health in terms of reduction
in mortality from breast cancer. However, for each woman the
choice is clear: on the plus side, screening confers reduction in the
risk of mortality from breast cancer because of early detection
and treatment. On the negative side, is the knowledge that
she has perhaps a 1% chance of having a cancer diagnosed and
treated that would never have caused problems had she not been
screened.
Evidence from a focus group the panel conducted, and in line
with previous similar studies, was that screening was an offer many
women will feel is worth accepting: the treatment of overdiagnosed
cancer may cause suffering and anxiety but that suffering is worth
the gain from the potential reduction in breast cancer mortality.
Clear communication of these harms and benefits to women is of
utmost importance and goes to the heart of how a modern health
system should function. There is a body of knowledge on how
women want information presented, and this should inform the
design of information to the public.
APPENDIX 1. TERMS OF REFERENCE, REVIEW PROCESS AND ROLE OF THE SECRETARIAT
Terms of Reference for the breast screening review
The overall aim of the review is to develop an up-to-date (2012)
assessment of both the benefits and harms associated with
population breast screening programmes. This is a rigorous review
of the evidence by an independent panel; it is not a formal
systematic review.
The review has been commissioned by Professor Sir Mike
Richards, National Cancer Director, England, and Dr Harpal
Kumar, Chief Executive of Cancer Research UK.
Up to six independent experts will be appointed to undertake
the review. These experts will be nationally and internationally
recognised for their expertise in epidemiology and/or medical
statistics as well as in current breast cancer diagnosis and
treatment, but will not have previously published on the topic of
breast screening.
The reviewers will be supported in their work by a small team
based at Cancer Research UK who will assist with the collation of
relevant research papers and will facilitate the work of the panel.
Additional funding for the review will be provided from the
Department of Health.
Scope
The reviewers will be asked to consider both the evidence from
RCTs of breast screening and from observational studies, including
prospective follow-up and case–control studies, of the impact of
breast screening programmes both in the United Kingodm and
elsewhere.
Evidence for the review will be limited to research that has been
published or accepted for publication.
The most recent publications from each source (e.g., RCT or
cohort) should be considered, but the reviewers may also choose to
consider earlier publications from the same source.
In addition to considering individual studies, the reviewers will be
asked to consider published systematic reviews and/or meta-analyses
of breast screening in different countries/jurisdictions. The reviewers
will also be asked to consider published methodology papers to
assess benefits and harms in breast screening studies.
The reviewers will be expected to understand the arguments that
have been made in various articles and opinion pieces regarding
the benefits and harms of breast screening. The focus, however, will
be on the evidence, thus articles providing opinions (either for or
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against breast screening) that do not contain original data or meta-
analyses will not be expected to have a bearing on the conclusions
of the review.
Outputs
The key outputs of the review will be:
 An estimate of the likely benefits of breast screening and the
range of uncertainty in this estimate.
 An estimate of the likely harms of breast screening and in
particular the risks of overdiagnosis and the range of uncertainty
in this estimate (i.e., patients being diagnosed and treated for
cancer that would not have caused problems during their
lifetime).
The review will comment on overall effectiveness of screening
which, in addition to the above, will depend on participation rates
and developments in effective treatment.
If the available evidence permits, assessments of benefits and
harms should also be made for different age groups and for
different subgroups (e.g., DCIS diagnoses, and socioeconomic, and
ethnic groups).
Approach to the review
It will be for the independent reviewers to determine how
they wish to conduct the review. In addition to reviewing the
published evidence, it is likely they will choose to consult a range
of experts in breast screening who have published in this field.
These experts could include epidemiologists, statisticians or
clinicians. Consultation may be via written communications,
interviews, or workshops.
Regular updates on the process of the review will be
made available by Cancer Research UK (through a dedicated
page on the Cancer Research UK website (http://www.cruk.org.uk/
breastscreeningreview).
Reporting
The reviewers will be asked to prepare a report for publication by
Cancer Research UK. The outputs of the report may also be
published in peer-reviewed journals. On completion, the report
will be shared with the UK National Screening Committee (NSC)
and with Ministers in England, but the NSC will have no input to
the content of the report.
It is expected that the initial report will be published by spring/
summer 2012. However, it is conceivable that, at that stage, the
over-riding view of the independent review group is that further
primary research is needed to develop definitive conclusions. If this
is the case, the review will make recommendations regarding the
balance of evidence as it currently stands.
It is further expected that the review will make recommenda-
tions on key messages regarding risks and uncertainty that need to
be considered when drafting new communications materials
regarding the breast screening programme. This will include
considerations of effectiveness.
Review process
As outlined in section 2, the panel called on a range of experts to
give evidence. The expert witnesses who have presented evidence
to the panel and debated points relevant to the review are:
Philippe Autier, Vice President, Population Research, Interna-
tional Prevention Research Institute (iPRI), Lyon, France
Michael Baum, current Director of the Clinical Trials Group at
University College London,Professor Emeritus of surgery and visiting
Professor of medical humanities, University College London
Dame Valerie Beral, Professor of Epidemiology and Director,
Cancer Epidemiology Unit, University of Oxford
Susan Bewley, Consultant Obstetrician and Honorary Senior
Lecturer at King’s College London
Stephen Duffy, Professor of Cancer Screening, Wolfson
Institute of Preventative Medicine, at Barts and the London School
of Medicine and Dentistry, part of Queen Mary University
London, UK.
Harry de Koning, Professor of Screening Evaluation, Erasmus
MC, Rotterdam, the Netherlands
Ian Ellis, Professor of Cancer Pathology, University of
Nottingham
Peter Gøtzsche, Director, Nordic Cochrane Centre, Copenha-
gen, Denmark
Klim McPherson, Emeritus Fellow, Visiting Professor of Public
Health Epidemiology, Oxford University
Albert Mulley, Director, The Dartmouth Centre for Health Care
Delivery Science and Professor of Medicine, Dartmouth Medical
School, Dartmouth, USA
Lennarth Nystro¨m, Associate Professor, Department of Public
Health and Clinical Medicine, Umea University, Sweden
Julietta Patnick, Director, NHS Cancer Screening Programmes
and Visiting Professor, University of Oxford
Sir Richard Peto, Professor of Medical Statistics & Epidemiology,
Co-director of the Clinical Trial Service Unit, University of Oxford
Paul Pharoah, Professor of Cancer Epidemiology, University of
Cambridge
Sir Nick Wald, Institute Director, Wolfson Institute of
Preventive Medicine, Barts and the London Medical School
Jane Wardle, Professor in Clinical Psychology and Director,
Health Behaviour Unit, University College London
Robin Wilson, Consultant Radiologist, The Royal Marsden,
London
These expert witnesses also suggested additional scientific
evidence for consideration by the panel and provided follow-up
information on their evidence, if requested by the panel. The
secretariat organised and attended each witness session but did not
participate in any discussions. The commissioners of the
independent review, Professor Sir Mike Richards and Dr Harpal
Kumar attended some of these sessions but only as observers; they
did not participate in any discussions or pose any questions to
either the panel or the expert witnesses.
Role of the secretariat
Cancer Research UK and Department of Health provided the
secretariat, acting purely as support to the panel in the practical,
writing, and dissemination functions, and having no say in the
conclusions or recommendations.
In addition, the secretariat collated a bibliography of all
scientific research papers and reports that had been brought to
the panel’s attention by experts from both sides of the screening
debate. The secretariat also provided additional specific research
papers that the panel wished to consider. In addition to providing
the modelling study, showing the impact the various assumptions
used to calculate the level of ‘overdiagnosis’ can have on these
estimates (Appendix 6), Nick Ormiston-Smith provided cancer
incidence, mortality, and survival statistics and ran statistical
analyses as requested and instructed by panel members. The
secretariat also organised a focus group with women of screening
age in collaboration with the Cancer Research UK Health
Behaviour Research Centre at University College London, as
requested by the panel.
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APPENDIX 2. CHANGES IN BREAST CANCER MANAGEMENT AND MORTALITY
Since the late 1980s, there have been three main changes in breast
cancer management:
 Treatment
 Organisation of services
 Population screening
Treatment
Surgery: There has been a shift from mastectomy to breast
conservation (lumpectomy and radiotherapy), formal staging of
the axilla, latterly by sentinel node biopsy.
Radiotherapy: Trials have established the role of radiotherapy,
following lumpectomy and, for selected patients, following
mastectomy.
Adjuvant systemic therapy: Trials have established that for
patients with oestrogen receptor (ER)-positive invasive breast
cancer, tamoxifen (or for postmenopausal patients, aromatase
inhibitors) reduce the risk of relapse and improve long-
term survival. Adjuvant chemotherapy was initially intro-
duced for high-risk premenopausal patients, using the CMF
regime, then, as its benefits were appreciated, postmenopausal
and lower-risk patients, were also treated and anthracycline- and/
or taxane-containing regimens were also used (with further
benefit). More recently, for the minority of women with HER2-
positive breast cancer treated with chemotherapy, trials have
confirmed that the addition of trastuzumab further improves
survival.
Organisation of services
The management of breast cancer in the United Kingdom
was considered part of general surgery, pathology, radiology,
and oncology. There has been shift (in part due to the setting up
of specialist screening services) to all breast cancer patients being
seen in specialist units and decisions about management being
considered at specialist multidisciplinary team meetings. This was
an incremental process, and the improvements in, for example,
surgical staging have helped better targeting of treatment (e.g.,
knowledge of the nodal status assists selecting patients for
chemotherapy, knowing the ER status selects patients for adjuvant
hormone therapy).
Screening
Most of the issues about screening are discussed elsewhere in
this report.
Changes in mortality
The graph (Figure A2) shows the changes in breast cancer
mortality for different age groups over a 40-year period.
The increases in mortality seen in the early period (1971 to mid
1980s) presumably follow on from the increase in incidence. The pattern
by age follows that of the incidence changes with the peak incidence in
older patients and little change in the under 50s. This is what one would
expect if there was little change in treatment (as was the case).
The fall in breast cancer mortality starts in the late 1980s, affects
all age groups, and has continued to 2007. The figures in the table
below examine these changes in more detail (GROS 2010, ONS
2011, NISRA 2011). Deaths from breast cancer can be expressed as
standardised mortality rates, which are very useful for comparing
populations, but also as absolute numbers of deaths, reflecting the
realities in terms of the burden on the health service.
Table A2. Changes in breast cancer mortality and the contribution of
breast cancer as a cause of death for the years 1998–90 and 2008–10,
by age groups
Age groups (years)
40–49 50–59 60–69 70–79 80–84
Average numbers of breast cancer deaths/year
1988/90 1415 2590 3516 3720 1662
2008/10 1000 1681 2354 2655 1498
Reduction (%) 415 (29) 909 (35) 1162 (33) 1065 (29) 164 (10)
Breast cancer mortality
1988/90 39.0 81.5 115.1 151.2 214.0
2008/10 21.1 43.2 68.9 107.1 167.3
Reduction (%) 17.9 (46) 38.3 (47) 46.2 (40) 44.1 (29) 46.7 (22)
No. of deaths (female)/year
1988/90 6712 15 947 45 567 89 289 64 641
2008/10 6659 13 612 28 347 57 884 50 557
Reduction (%) 53 (1) 2335 (15) 17 220 (38) 31 405 (35) 14 084 (21.8)
Breast cancer deaths as % of all deaths
1988/90 21.1 16.2 7.7 4.2 2.6
2008/10 15.0 12.3 8.3 4.6 3.0
Change  6.1  3.9 þ 0.6 þ 0.4 þ 0.4
GROS, 2010; ONS, 2011; NISRA, 2011
The figures confirm a reduction in both the breast cancer
mortality and the absolute number of deaths from breast cancer in
all age groups. It should, however, be noted that:
 the reduction in breast cancer mortality is most marked in the
under 70s.
 breast cancer mortality rises markedly with age, but the relative
contribution of breast cancer deaths to the total number of
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Figure A2. European age-standardised mortality rates, breast cancer, women, by age, UK 1971–2010. (Cancer Research UK, 2012).
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deaths falls with age (reflecting the increase in other causes of
death with age).
 accompanying the fall in breast cancer mortality and deaths,
there has been a marked fall in other causes of death, particularly
in the 60–79 age group.
 the net effect is that the relative contribution of breast cancer to
total deaths has fallen in those o59 years but has (modestly)
risen in those aged X60.
The screening programme would be expected to impact only on
the deaths of womenX55 years, and it is apparent from the figures
that the overall effect on mortality will be attenuated by the impact
of other causes of death. (e.g., in the 70–79 age group, breast cancer
accounts for o5% of all female deaths).
It should also be noted that breast cancer mortality rates vary by
country. Breast cancer mortality in the United Kingdom in the late
1980s was about 40 (per 100 000 population), whereas in Sweden
(where many of the screening trials were carried out) and Norway
it was about 26. The undoubted improvements in the United
Kingdom mortality have only brought it down to the starting level
in Sweden/Norway (where it was down to 22 by 2006).
Comparisons of mortality need to include both absolute levels
and changes and understanding of the reasons for baseline
differences.
Conclusion
Many of the early trials of adjuvant therapy occurred concurrently
with the screening trials, and so the changes mentioned above were
introduced concurrently with the introduction of screening.
It is thus difficult to disaggregate the individual contributions of
each to the undoubted improvements in breast cancer mortality.
The organisational changes are not the product of RCTs and are
multifaceted, so their contribution, although probably real (Kesson
et al, 2012), is the most difficult to quantify. There has been a
significant improvement in breast cancer mortality in all ages, part
of which is certainly due to improvements in treatment. Changes
in mortality also reflect factors affecting incidence as well as
presentation and organisational arrangements. Crude mortality
statistics are the summation if these factors but do not of
themselves indicate the relative contributions.
APPENDIX 3. CASE–CONTROL STUDIES
Case–control study selection
General medical literature was searched using PubMed for the period
1970 to present in order to identify case–control studies that assessed the
effect of screening mammography on breast cancer mortality. The
following search terms were used in locating the articles, ‘breast cancer’,
‘screening’, ‘screening mammography’, ‘breast cancer mortality’, ‘breast
cancer death’, ‘screening case–control’ and ‘screening case referent’.
A total of 21 case–control studies (see Table A3) were identified
as considering breast cancer mortality and compared against a list of
case–control references shared by expert witnesses. The case–control
studies showed breast screening to confer a greater benefit than did the
trials. Although these studies, in general, attempted to control for non-
comparability of screened and unscreened women, the panel was
concerned that residual bias could inflate the estimate of benefit. There
were also a larger number of case–control studies investigating compa-
risons between lifestyle risk factors and detection of abnormalities at
screening, and early- and late-stage cancers. These latter studies were not
used, as they did not directly provide an estimate of screening benefit.
Table A3. Overview of the characteristics of the case–control studies considered and their methods for correcting for self-selection bias
Study/reference
year
Age group
studied Controls Self-selection adjustment
Unadjusted odds ratio of
breast cancer mortality in
women attending screening
vs those who did not
(95% CI) age groups not
reported where combined
figure available
Adjusted odds ratio
of breast cancer
mortality in women
attending screening
vs those that did
not (95% CI)
Gullberg et al, 1991 Not reported Matched by age Adjustment considered but not
made
0.42 (0.22–0.78) N/A
Palli et al, 1989 40–69 at
diagnosis
5 Matched by year of birth
and residence
Adjustment has been attempted
using proxy variables
Age 40–49: 0.63 (0.24–1.64)
Age 50–69: 0.51 (0.29–0.89)
Age 40–49: 1.46 (0.36–5.93)
Age 50–69: 0.35 (0.14–0.85)a
Puliti et al, 2008 Residents aged
50–74
4 Matched by date of birth
and residence
Adjustment using
women in areas where the breast
screening was not underway.
0.46 (0.38–0.56) 0.55 (0.36–0.85)b
Collette et al, 1984 50–64 at study
entry
3 Matched by year of birth
and residence
Adjustment considered but not
made
0.30 (0.13–0.70) N/A
Miltenburg et al,
1998
50–69 at first
invitation
3 Matched by year of birth,
invitation and residence
Adjustment considered but not
made
0.54 (0.37–0.79) N/A
Verbeek et al,
1984
35–65 at first
invitation
5 Matched by year of birth Adjustment considered but not
made
0.48 (0.23–1.00) N/A
Verbeek et al,
1985
35–65 at first
invitation
5 Matched by year of birth Adjustment considered but not
made
0.51 (0.26–0.99) N/A
Van Dijck et al,
1996
65–92 at last
invitation
5 Matched by age and
invitation
Adjustment considered but not
made
0.56 (0.28–1.13) N/A
Broeders et al,
2002
35þ at first
invitation
5 Matched by age, invitation
and residence
Adjustment considered but not
made
Age 40–49: 0.84 (0.30–2.29)
Age 50–59: 0.65 (0.30–1.42)
Age 60–69: 0.65 (0.31–1.28)
Age 70–79: 0.70 (0.32–1.54)
N/A
Van Schoor et al,
2010
40–69 at
invitation
Age 40–49: 0.50 (0.30–0.82)
Age 50–59: 0.54 (0.35–0.85)
Age 60–69: 0.65 (0.38–1.13)
N/A
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Table A3. ( Continued )
Study/reference
year
Age group
studied Controls Self-selection adjustment
Unadjusted odds ratio of
breast cancer mortality in
women attending screening
vs those who did not
(95% CI) age groups not
reported where combined
figure available
Adjusted odds ratio
of breast cancer
mortality in women
attending screening
vs those that did
not (95% CI)
Van Schoor et al,
2011
50–69 at
invitation
5 Matched by residence Adjustment using the Duffy
method
— 0.65 (0.49–0.87)
Paap et al, 2010 50–75 at
invitation
1 Matched by year of birth
and residence
Adjustment using the Duffy
method
0.30 (0.14–0.63) 0.24 (0.10–0.58)b
Otto et al, 2012 49–75 at first
invitation
1 Matched by invitation and
year of birth
Adjustment using women in
same area before breast
screening.
0.45 (0.37–0.54) 0.51 (0.40–0.66)b
Friedman and
Dubin, 1991
40–64 at entry 4 Matched by survival and
year of birth
Adjustment considered but not
made
0.75 (0.60–0.93) N/A
Norman et al,
2007
40–64 at entry Matched within
original random control
group
Adjustment considered but not
made
Age 40–49: 0.89 (0.65–1.23)
Age 50–64: 0.47 (0.35–0.63)
N/A
Elmore et al, 2005 40–65 at
diagnosis
1 Matched by age, risk and
health plan
Adjustment considered but not
made
0.92 (0.79–1.08)c 0.92 (0.79–1.08)c
Moss et al, 1992 45–64 at entry 5 Matched on age at entry
to trial and residence
Adjustment considered but not
made
0.51 (0.27–0.98)d N/A
Fielder et al, 2004 50–74 at
diagnosis
5 Matched on year of birth
and GP Practise
Adjustment using the Duffy
method
0.49 (0.36–0.66) 0.75 (0.49–1.14)b
Allgood et al,
2008
50–70 at
diagnosis
2 Matched on year of birth Adjustment using the Duffy
method
0.35 (0.24–0.50) 0.52 (0.32–0.84)b
Roder et al, 2008 45–80 at death
of cases
3 Matched on date of birth Adjustment has been attempted
using socio-economic status
0.59 (0.47–0.74)
Gabe et al, 2007 X40 at death 3/4 Matched by date of birth
and residence
Adjustment using the Duffy
method
0.59 (0.41–0.84) 0.65 (0.39–1.09)b
Abbreviations: CI¼ confidence interval; IMPACT, DOM, CARE¼Women’s Contraceptive and Reproductive Experiences Study; HIP¼ health insurance plan; OR¼odds ratio; TEDBC¼ trial of
early detection of breast cancer. Odds ratios for age groups have been presented where an overall odds ratio is not available.
aAt least 2 examinations and last screen o30 months.
bCorrected for self-selection bias.
cCombined risk groups, screening by mammogram.
dOutcome of the analysis conducted solely in the screening district.
APPENDIX 4. FORMULAE USED TO CALCULATE OVERDIAGNOSIS
Formulae for calculating overdiagnosis from de Gelder et al (2011):
(ED)/T0, age 0–100 years: the relative increase in breast cancers
due to overdiagnosis (ED) compared with the predicted number
of breast cancers in the female population aged 0–100 years in a
situation without screening.
(ED)/T0, screening age and older: the relative increase in breast
cancers due to overdiagnosis (ED) compared with the predicted
number of breast cancers in women of the screening age and older
in a situation without screening.
(ED)/T0, screening age: the relative increase in breast cancers due to
overdiagnosis compared with the predicted number of breast cancers
in women of the screening age in a situation without screening.
(ED)/T1, screening age: the fraction of overdiagnosed cancers of
all diagnosed breast cancers in women of the screening age in a
situation with screening.
(ED)/SD: the fraction of all screen-detected (SD) cancers that
is overdiagnosed.
T1, screening age/T0, screening age: the RR of breast cancer for women
of the screening age in a situation with screening compared with
the predicted number of breast cancers in women of the same age
in a situation without screening. The estimator can be corrected for
lead time for instance, by shifting the predicted incidence without
screening forward in time.
T1, screening age/(T1, screening age, corrected): the RR of breast cancer for
women of the screening age in a situation with screening compared
with the predicted number of tumors in a situation with screening if
no overdiagnosis would take place (T1, screening age, corrected).
Abbreviations:
D: number of deficit breast cancers in the age groups exceeding the
screening limit, calculated as the difference in the number of breast
cancers without and with screening; DCIS: ductal cacinoma in situ;
E: number of excess breast cancers in the screening ages, calculated
as the difference in the number of breast cancers with and without
screening; SD: number of screen-detected cancers; T0: predicted
number of breast cancers in the absence of screening; T1: modelled
total number of breast cancers in the presence of screening; T1, corr:
total number of breast cancers in the presence of screening minus
the number of overdiagnosed cancers.
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APPENDIX 5. FOCUS GROUP
Overview
Nine women from the London area and within the breast
screening age range (50–71 years) were invited to join a focus
group to discuss their reasons for attending screening or not, and
to comment on information on the risk of overdiagnosis and DCIS.
All women spoke fluent English, had no previous personal history
of cancer and came from a range of socioeconomic backgrounds.
These women were recruited from a market research recruitment
database, hosted by Saros (http://www.saros-research-recruitment.-
com). Saros screened eligible participants via email or phone. The
group was facilitated by Dr Jo Waller from the Cancer Research
UK Health Behaviour Research Centre at University College
London and observed by two panel members.
Findings
Accepting or declining an invitation to screen: Seven out of the nine
attendees had accepted an invitation to be screened in the past,
which is close to the current UK average. The main reasons
expressed for attending were an assumed feeling that attending
screening is beneficial (the perceived benefits are that finding the
disease earlier means better outcomes and that a negative scan
provides peace of mind), awareness of breast cancer (‘lots of people
are getting it’) and the fact that you receive a specific invitation to
attend. The main reason mentioned for not attending was the
anticipated pain of the actual mammogram and the embarrass-
ment of the technique. Some of the women who had previously
attended screening had experienced discomfort and mentioned
that this might deter them from accepting another invitation in the
future. There was a general consensus among the group that no
screening programme can be perfect, and that some cancers may
be missed but the women had not been particularly aware of DCIS
and overdiagnosis. The screening attendees felt that the screening
programme was well organised, but most agreed that they would be
less likely to attend if not specifically invited.
The knowledge that you may be diagnosed with and treated for
a slow growing tumour that would never have caused you
problems in your lifetime did not appear to change this group’s
intention to accept another screening invitation. There was a
general consensus, in this group and others, that attending
screening and possible subsequent decisions on treatment if cancer
or DCIS are found were two separate issues.
The women were surprised, however, to learn that doctors
cannot always tell whether a tumour is likely to cause harm or not,
but felt that the treatment decision was one to be made by
the woman after discussions with their consultant. There was a
feeling that doctors would not recommend treatment for cancer if
they did not think it was appropriate. This is in line with findings
from other qualitative research (Dr Jo Waller, personal
communication).
There was more concern about the potential radiation risk: ‘For
every 14 000 women screened regularly for 10 years, one woman
may develop breast cancer she will die from because of the
radiation from the mammograms’ (NHS Breast Screening leaflet,
2011) and the high number of women recalled for further tests
after the initial mammogram (about one in every 20 screened),
rather than the concept of overdiagnosis.
Information about screening: Some of the women in this focus
group expected the information in the breast screening leaflet to
boost uptake of screening invitations, and felt that it should therefore
be written in non-alarmist terms. Many could not recall whether
they had read the leaflet when they were last invited and nobody
could remember what information it actually contained. The women
indicated that their decision to accept or decline an invitation to
screen was unlikely to be influenced by information in this leaflet.
This group also expected the leaflet to focus on what to expect when
attending for a screen, notably the procedure of the mammogram.
However, they also felt that some basic information about risks and
benefits should be included for those women who wanted it.
Table A5. Focus group characteristics
Ethnicity No. Current employment No.
Black Caribbean 2 Employed full time 1
White British 7 Employed part time 3
Other 0 Unemployed 0
Marital status Self-employed 1
Single/never married 2 Full-time homemaker 0
Married/living with partner 1 Retired 3
Divorced 5 Still studying 0
Widowed 1 Disabled or too to work 0
No answer 1
Highest level of education qualifica-
tion obtained
Does your household own a
car or van?
Degree or higher degree 5 No 2
Higher education qualification
below degree level
1 Yes, one 5
A-levels or highers 0 Yes, two or more 1
ONC/BTEC 0 No answer 1
O level or GCSE equivalent (Grade
A–C)
2 Have you been screened for
breast cancer? (i.e., had a
mammogram)
O level or GCSE (Grade D–G) 1 Yes 6
No formal qualifications 0 No 2
Current living arrangements When was your last mammo-
gram? (Open text)
Home owned outright 3 No answer 3
Home owned with mortgage 3 Cannot remember 1
Rent from local authority/housing
association
2 2007 2
rent privately 0 2010 3
Other (e.g., living with family/
friends)
0 Have you ever been called
back for further tests after
your mammogram?
No answer 1 Yes 2
No 6
No answer 1
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APPENDIX 6. MODELLING OVERDIAGNOSIS USING TIME TRENDS
Introduction
The most reliable estimates of overdiagnosis come from three
RCTs in which women in the control group were not offered
screening at the end of the trial. However, these randomised trials
of breast screening date from the 1980s or earlier. The setting of
the trials is not necessarily directly comparable with the current
screening programme (for example, because of different technol-
ogy used in mammography and changes in the underlying breast
cancer risk). Many researchers have therefore attempted to use
observational studies to estimate the extent of overdiagnosis
contemporaneously.
One method of estimating the level of overdiagnosis is the
extrapolation method (ONS, 2012). This method predicts the
expected level of breast cancer if there were to be no mammography
screening, and compares it with the actual observed level.
Estimates produced using this basic extrapolation method differ
for a number of reasons, but one reason for different estimates is
the choice of assumptions used in the modelling (ONS, 2012). A
number of models were therefore run to consider the effect of
applying different assumptions and the impact this has on the
estimate of overdiagnosis due to breast screening.
Methods
The method predicts the expected level of breast cancer diagnosis
in the age group targeted for screening in the absence of screening
using a regression model, and then calculates the difference
between this expected level and the observed data; the excess due to
screening (Figure A6.1). Similar analysis for the older-age group
was then undertaken to calculate the size of a compensatory drop.
Compensatory drop is the relative decrease in the incidence of a
cancer in a screened population compared with an unscreened
population, once screening stops. This is because screening detects
the cancer earlier, so cases that would have presented symptoma-
tically have already been diagnosed during screening. The overall
estimate of overdiagnosis is therefore the number of excess cases
due to screening minus the size of this compensatory drop. This
was calculated for each year in the analysis and the average taken
so that the results from all the models with different periods could
be compared.
This extrapolation method assumes that the risk of breast cancer
has increased at a constant rate, as the period used to estimate the
expected level of breast cancer ends. In addition, it assumes that
the quality of case ascertainment by registries and diagnostic
methods has remained stable over time.
Models
In total, 2250 regression models, using both linear and Poisson
regression, were applied to the age-specific incidence rates in
England from 1975 to 2004 using a combination of different
assumptions, and a range of different overdiagnosis estimates were
produced. The assumptions examined were:
 the pre-screening era period, this varied from 1975–1984 to
1975–1988 (and all intermediate years).
 the target-screening age group, this included age groups 50–64,
45–64 and Poisson regression models, which considered two age
categories separately 45–49 and 50–64
 the post-screening age group, this included age groups 65–74, all
women X65 and Poisson regression models, which considered
two age categories 65–69 and all women X70.
 the screening era period, the start of the screening period was
allowed to vary between 1989 and 1993 and the end from 2002
to 2004.
Table A6.1 set outs the different model specifications used in the
modelling.
Table A6.1. The different assumptions in the published models
Model spec Assumptions
Regression technique Linear regression on rates and Poisson regression on counts
Pre-screening era year end 1984 through to 1988
Screening age group 50–64, 45–49 and 50–64, and 45–64
Post-screening age group 65–74, 65–69 and 70 and over, and 65 plus
Screening era All combinations starting with 1989–1993 and ending in
2002–2004
Compensatory drop
adjustment
Rate ratio and difference of counts
Risk adjustment None and for increasing trend in under 45s
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Figure A6.1. Breast cancer age-specific incidence rates, England 1975–2008. Description to include: breast cancer age-specific incidence rates,
England 1975–2008, age 50–64 with expected, observed and smoothed data.
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Standard Models: All of the combinations of age groups and
time periods, described above, were modelled using both
linear regression (300 models) and Poisson regression (675
models). These analyses are known here as the standard regression
models.
Calculation of the Compensatory Drop: In addition to the
standard models described above, the calculation of the compen-
satory drop (using either count or rate ratio) was investigated. The
results of the standard regression models have been expressed
using the difference of counts in the observed and expected data.
To investigate the effect of calculating the compensatory drop
using a different method the outcome of the linear regression
standard models using the difference of counts were compared
with the same models, but the compensatory drop was calculated
using the rate ratio of the observed and expected data. This analysis
was repeated but the rate ratio was only applied to the final year in
each set of linear regression results.
Model Adjustment: Finally, an adjustment was applied to the
standard Poisson regression model estimates to take account of
increasing incidence in the mostly unscreened under 45 age group.
These results were compared with the standard Poisson regression
model estimates.
Results
The results of the 2250 regression models produced a range of
estimates from 0 to 6552 or 214 per 10 000 women invited to
screening (Figure A6.2). A total of 10% of the results were o1150
(or 37 per 10 000 women invited to screening) and 10% above 4115
(or 134 per 10 000 women invited to screening). These figures are
not directly comparable with the 129 per 10 000 women invited to
screening in the main report because they do not include DCIS.
Three assumptions had the biggest effect on the results of the
modelling: the adjustments made to the regression technique, end
of pre-screening era, and target age group.
Standard Models: Choosing a standard Poisson regression model
rather than a standard linear regression model increases the estimates
of over diagnosis by an average of 316 women per year (range
80–476). The choice of target age group 50–64 rather than the age
group 45–64 reduced the estimates of over diagnosis by an average of
379 across all of the regression models. Increasing the length of the
pre-screening era from 1984 to 1988 reduced the estimates of
overdiagnosis by an average of 1083, using the linear regression
models and 1314 in the Poisson regression models. The length of the
pre-screening era, which varied from 1975 to 1984 or 1988 (and all
years in between) has an impact because there has been an increase in
the rate of breast cancer diagnosis in this 5-year period.
The effects of the length of the screening era and the age
groups used in the post-target age group had much less of an
effect. Starting the screening era at 1991, on average, had the
biggest effect and increased the over diagnosis estimate by 123
women per year compared with 1993 (the lowest year) in the
standard linear regression model. In the standard Poisson
regression model, 1991 is the highest year that was 158 higher
than 1993 (the lowest estimate), on average, in the standard
Poisson regression model.
Calculation of the compensatory drop: When the rate ratio was
applied rather than the difference of counts to calculate the
compensatory drop on a set of standard linear regression estimates,
the estimates of overdiagnosis were increased by, on average, 295
women per year. If only the last year of the screening period was
used rather than the average across all years, then this method
increased the estimate overdiagnosis by 1469 women per year on
average. This difference was primarily driven by the choice of the
pre-screening era (1984 through to 1988), which in the standard
linear regression model can differ by up to 1083 women
(Table A6.2) but using the rate ratio method and the last year
the estimate varied by an average of 2420 women.
Model adjustment: Applying an adjustment to take account of
increasing incidence in women under 45 years to the standard
Poisson regression model estimates reduced the estimates, on
average, by 1161 women. This was also driven by the length of the
pre-screening era, but the results were not incremental in the same
way as the linear regression results. The models that used 1984 and
1985 as the end of the pre-screening era had very low estimates and
the models that used 1986, 1987, and 1988 had relatively larger
estimates.
Conclusion
The best method of assessing both the positives and negatives of
breast screening would be a randomised control trial. However, in
the absence of an RCT and with publically available data, the level
of overdiagnosis can be estimated by extrapolation. However, the
results are sensitive to the assumptions used to set up the model,
and are limited by the age extension roll out between 2002
and 2004.
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Figure A6.2. Histogram of the range of estimates.
Table A6.2. Number of additional cases of overdiagnosed per year when
pre-screening era ends using the standard linear and Poisson regression
models
Year when
pre-screening
era ends
Number of additional
overdiagnosed cases
per year compared with
1988: linear regression
models
Number of additional
overdiagnosed cases per
year compared with
1988: Poisson regression
models
1984 1083 1314
1985 664 749
1986 468 565
1987 191 208
1988 0 0
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The decision on how to adjust the regression modelling has the
biggest impact on the results. However, the adjustments to
the model that best represents the level of breast cancer would
be in the absence of screening is unclear.
This extrapolation method assumes that the risk of breast
cancer has increased at a constant rate as the period used
to estimate the expected level of breast cancer ends. In addition, it
assumes that the quality of case ascertainment by registries
and diagnostic methods has remained stable over time.
Although in theory it would be possible to adjust for these
effects, how to adjust for them in practice would create
further uncertainty in the estimates produced because different
methods would create a further range of possible overdiagnosis
estimates.
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